数据之源，洞见之始

Signaling by GPCR

Montezano AC, Kuriakose J, Hood KY, Sin YY, Camargo LL, Namkung Y, Castro CH, Santos RA, Alves-Lopes R, Tejeda G, Passaglia P, Basheer S, Gallen E, Findlay JE, Awan FR, Laporte SA, MacLean MR, Baillie GS, Touyz RM. Ang-(1-7) and ET-1 Interplay Through Mas and ETB Receptor Interaction Defines a Novel Vasoprotective Mechanism. Hypertension. 2025 Feb;82(2):267–81. doi: 10.1161/hypertensionaha.124.22693. PMID: 39633565.; Wang C, Liu Y, Lanier M, Yeager A, Singh I, Gumpper RH, Krumm BE, DeLeon C, Zhang S, Boehm M, Pittner R, Baron A, Dvorak L, Bacon C, Shoichet BK, Martinborough E, Fay JF, Cao C, Roth BL. High-affinity agonists reveal recognition motifs for the MRGPRD GPCR. Cell Reports. 2024 Dec;43(12):114942. doi: 10.1016/j.celrep.2024.114942.; Rukavina Mikusic NL, Silva MG, Erra Díaz FA, Pineda AM, Ferragut F, Gómez KA, Mazzitelli L, Gonzalez Maglio DH, Nuñez M, Santos RAS, Grecco HE, Gironacci MM. Alamandine, a protective component of the renin-angiotensin system, reduces cellular proliferation and interleukin-6 secretion in human macrophages through MasR-MrgDR heteromerization. Biochem Pharmacol. 2024 Nov;229():116480. doi: 10.1016/j.bcp.2024.116480. PMID: 39128587.; Bader M, Steckelings UM, Alenina N, Santos RAS, Ferrario CM. Alternative Renin-Angiotensin System. Hypertension. 2024 May;81(5):964–76. doi: 10.1161/hypertensionaha.123.21364.; Proença AB, Medeiros GR, Reis GDS, Losito LDF, Ferraz LM, Bargut TCL, Soares NP, Alexandre-Santos B, Campagnole-Santos MJ, Magliano DC, Nobrega ACLD, Santos RAS, Frantz EDC. Adipose tissue plasticity mediated by the counterregulatory axis of the renin-angiotensin system: Role of Mas and MrgD receptors. J Cell Physiol. 2024 Jun;239(6):e31265. doi: 10.1002/jcp.31265. PMID: 38577921.; Makkonen K, Jännäri M, Crisóstomo L, Kuusi M, Patyra K, Melnyk V, Linnossuo V, Ojala J, Ravi R, Löf C, Mäkelä JA, Miettinen P, Laakso S, Ojaniemi M, Jääskeläinen J, Laakso M, Bossowski F, Sawicka B, Stozek K, Bossowski A, Kleinau G, Scheerer P, FinnGen F, Reeve MP, Kero J. Mechanisms of thyrotropin receptor-mediated phenotype variability deciphered by gene mutations and M453T-knockin model. JCI Insight. 2024 Jan 09;9(4). PMID: 38194289; PMCID: PMC11143923.; Jing L, Zhang Q. Intrathyroidal feedforward and feedback network regulating thyroid hormone synthesis and secretion. Front Endocrinol (Lausanne). 2022;13():992883. PMID: 36187113; PMCID: PMC9519864.; Suzuki S, Iida M, Hiroaki Y, Tanaka K, Kawamoto A, Kato T, Oshima A. Structural insight into the activation mechanism of MrgD with heterotrimeric Gi-protein revealed by cryo-EM. Communications Biology. 2022 Jul 15;5(1):707. doi: 10.1038/s42003-022-03668-3.; Cheuiche AV, da Silveira LG, de Paula LCP, Lucena IRS, Silveiro SP. Diagnosis and management of precocious sexual maturation: an updated review. European Journal of Pediatrics. 2021 Mar 21;180(10):3073–87. doi: 10.1007/s00431-021-04022-1.; Zheng W, Wang Z, Jiang X, Zhao Q, Shen J. Targeted Drugs for Treatment of Pulmonary Arterial Hypertension: Past, Present, and Future Perspectives. J Med Chem. 2020 Dec 24;63(24):15153–86. doi: 10.1021/acs.jmedchem.0c01093. PMID: 33314936.; Shim YS, Lim KI, Lee HS, Hwang JS. Long-term outcomes after gonadotropin-releasing hormone agonist treatment in boys with central precocious puberty. PLoS ONE. 2020 Dec 10;15(12):e0243212. doi: 10.1371/journal.pone.0243212.; Tzoupis H, Nteli A, Androutsou ME, Tselios T. Gonadotropin-Releasing Hormone and GnRH Receptor: Structure, Function and Drug Development. Curr Med Chem. 2020;27(36):6136–58. doi: 10.2174/0929867326666190712165444. PMID: 31309882.; Maldonado V, Loza-Mejía MA, Chávez-Alderete J. Repositioning of pentoxifylline as an immunomodulator and regulator of the renin-angiotensin system in the treatment of COVID-19. Medical Hypotheses. 2020 Nov;144():109988. doi: 10.1016/j.mehy.2020.109988.; Ghasemnejad-Berenji M, Pashapour S, Sadeghpour S. Pentoxifylline: A Drug with Antiviral and Anti-Inflammatory Effects to Be Considered in the Treatment of Coronavirus Disease 2019. Med Princ Pract. 2021;30(1):98–100. PMID: 33049737; PMCID: PMC7923888.; Kappes L, Amer RL, Sommerlatte S, Bashir G, Plattfaut C, Gieseler F, Gemoll T, Busch H, Altahrawi A, Al-Sbiei A, Haneefa SM, Arafat K, Schimke LF, Khawanky NE, Schulze-Forster K, Heidecke H, Kerstein-Staehle A, Marschner G, Pitann S, Ochs HD, Mueller A, Attoub S, Fernandez-Cabezudo MJ, Riemekasten G, al-Ramadi BK, Cabral-Marques O. Ambrisentan, an endothelin receptor type A-selective antagonist, inhibits cancer cell migration, invasion, and metastasis. Scientific Reports. 2020 Sep 28;10(1):15931. doi: 10.1038/s41598-020-72960-1.; Donnez O, Donnez J. Gonadotropin-releasing hormone antagonist (linzagolix): a new therapy for uterine adenomyosis. Fertil Steril. 2020 Sep;114(3):640–5. doi: 10.1016/j.fertnstert.2020.04.017. PMID: 32507315.; Broessner G, Reuter U, Bonner JH, Dodick DW, Hallström Y, Picard H, Zhang F, Lenz RA, Klatt J, Mikol DD. The Spectrum of Response to Erenumab in Patients With Episodic Migraine and Subgroup Analysis of Patients Achieving =50%, =75%, and 100% Response. Headache. 2020 Oct;60(9):2026–40. PMID: 32851644; PMCID: PMC7590156.; Lane LC, Cheetham TD, Perros P, Pearce SHS. New Therapeutic Horizons for Graves' Hyperthyroidism. Endocr Rev. 2020 Dec 01;41(6). PMID: 32845332; PMCID: PMC7567404.; Goadsby PJ, Reuter U, Hallström Y, Broessner G, Bonner JH, Zhang F, Wright IK, Chou DE, Klatt J, Picard H, Lenz RA, Mikol DD. One-year sustained efficacy of erenumab in episodic migraine: Results of the STRIVE study. Neurology. 2020 Aug 04;95(5):e469–79. PMID: 32636324; PMCID: PMC7455346.; Dalamaga M, Karampela I, Mantzoros CS. Commentary: Phosphodiesterase 4 inhibitors as potential adjunct treatment targeting the cytokine storm in COVID-19. Metabolism. 2020 Aug;109():154282. doi: 10.1016/j.metabol.2020.154282.; Armesto S, González Vela C, Sánchez J, Illaro A, Mayorga J, López Sundh AE, Naharro Fernández C, Palmou N, Gómez-Fernández C, González López MA, González-Gay MA. Treating multidrug-resistant psoriasis with brodalumab, apremilast, methotrexate and prednisone combination therapy in the COVID-19 pandemic. Dermatol Ther. 2020 Nov;33(6):e14464. doi: 10.1111/dth.14464. PMID: 33112014.; Giorgi M, Cardarelli S, Ragusa F, Saliola M, Biagioni S, Poiana G, Naro F, Massimi M. Phosphodiesterase Inhibitors: Could They Be Beneficial for the Treatment of COVID-19? Int J Mol Sci. 2020 Jul 27;21(15). PMID: 32727145; PMCID: PMC7432892.; Hendry BM, Stafford N, Arnold AD, Sangwaiya A, Manglam V, Rosen SD, Arnold J. Hypothesis: Pentoxifylline is a potential cytokine modulator therapeutic in COVID-19 patients. Pharmacol Res Perspect. 2020 Aug;8(4):e00631. PMID: 32715661; PMCID: PMC7383088.; Donnez J, Taylor HS, Taylor RN, Akin MD, Tatarchuk TF, Wilk K, Gotteland JP, Lecomte V, Bestel E. Treatment of endometriosis-associated pain with linzagolix, an oral gonadotropin-releasing hormone-antagonist: a randomized clinical trial. Fertil Steril. 2020 Jul;114(1):44–55. doi: 10.1016/j.fertnstert.2020.02.114. PMID: 32505383.; Shore ND, Saad F, Cookson MS, George DJ, Saltzstein DR, Tutrone R, Akaza H, Bossi A, van Veenhuyzen DF, Selby B, Fan X, Kang V, Walling J, Tombal B; HERO Study Investigators. Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer. N Engl J Med. 2020 Jun 04;382(23):2187–96. doi: 10.1056/nejmoa2004325. PMID: 32469183.; Stephenson A, Lau L, Eszlinger M, Paschke R. The Thyrotropin Receptor Mutation Database Update. Thyroid. 2020 Jun;30(6):931–5. doi: 10.1089/thy.2019.0807. PMID: 32111150.; Spindler BL, Ryan M. Medications Approved for Preventing Migraine Headaches. The American Journal of Medicine. 2020 Jun;133(6):664–7. doi: 10.1016/j.amjmed.2020.01.031.; Dhillon S. Eptinezumab: First Approval. Drugs. 2020 May;80(7):733–9. doi: 10.1007/s40265-020-01300-4. PMID: 32266704.; Farkas K, Kolossváry E, Járai Z. Simple assessment of quality of life and lower limb functional capacity during cilostazol treatment - results of the SHort-tERm cIlostazol eFFicacy and quality of life (SHERIFF) study. Vasa. 2020 Apr;49(3):235–42. doi: 10.1024/0301-1526/a000845. PMID: 31983287.; Franco I, Hoebeke P, Baka-Ostrowska M, Bolong D, Davies LN, Dahler E, Snijder R, Stroosma O, Verheggen F, Newgreen D, Bosman B, Vande Walle J. Long-term efficacy and safety of solifenacin in pediatric patients aged 6 months to 18 years with neurogenic detrusor overactivity: results from two phase 3 prospective open-label studies. J Pediatr Urol. 2020 Apr;16(2):180.e1–8. doi: 10.1016/j.jpurol.2019.12.012. PMID: 32007426.; Phillips JE. Inhaled Phosphodiesterase 4 (PDE4) Inhibitors for Inflammatory Respiratory Diseases. Front. Pharmacol. 2020 Mar 12;11(). doi: 10.3389/fphar.2020.00259.; Hashim PW, Chima M, Kim HJ, Bares J, Yao CJ, Singer G, Chen T, Genece J, Baum D, Kimmel GW, Nia JK, Gagliotti M, Lebwohl MG. Crisaborole 2% ointment for the treatment of intertriginous, anogenital, and facial psoriasis: A double-blind, randomized, vehicle-controlled trial. Journal of the American Academy of Dermatology. 2020 Feb;82(2):360–5. doi: 10.1016/j.jaad.2019.06.1288.; Wendell SG, Fan H, Zhang C. G Protein–Coupled Receptors in Asthma Therapy: Pharmacology and Drug Action. Pharmacological Reviews. 2020 Jan;72(1):1–49. doi: 10.1124/pr.118.016899.; Dodick DW, Lipton RB, Ailani J, Lu K, Finnegan M, Trugman JM, Szegedi A. Ubrogepant for the Treatment of Migraine. N Engl J Med. 2019 Dec 05;381(23):2230–41. doi: 10.1056/nejmoa1813049. PMID: 31800988.; Fingeret M, Gaddie IB, Bloomenstein M. Latanoprostene bunod ophthalmic solution 0.024%: a new treatment option for open-angle glaucoma and ocular hypertension. Clinical and Experimental Optometry. 2019 Nov 01;102(6):541–50. doi: 10.1111/cxo.12853.; Akizawa T, Ikejiri K, Kondo Y, Endo Y, Fukagawa M. Evocalcet: A New Oral Calcimimetic for Dialysis Patients With Secondary Hyperparathyroidism. Ther Apher Dial. 2020 Jun;24(3):248–57. PMID: 31486206; PMCID: PMC7317959.; Fein MN, Fischer DA, O’Keefe AW, Sussman GL. CSACI position statement: Newer generation H1-antihistamines are safer than first-generation H1-antihistamines and should be the first-line antihistamines for the treatment of allergic rhinitis and urticaria. Allergy, Asthma & Clinical Immunology. 2019 Oct 01;15(1):61. doi: 10.1186/s13223-019-0375-9.; Chan C, Goadsby PJ. Recent Advances in Pharmacotherapy for Episodic Migraine. CNS Drugs. 2019 Nov;33(11):1053–71. doi: 10.1007/s40263-019-00665-9. PMID: 31556018.; Croop R, Goadsby PJ, Stock DA, Conway CM, Forshaw M, Stock EG, Coric V, Lipton RB. Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial. Lancet. 2019 Aug 31;394(10200):737–45. doi: 10.1016/s0140-6736(19)31606-x. PMID: 31311674.; Taylor HS, Dun EC, Chwalisz K. Clinical evaluation of the oral gonadotropin-releasing hormone-antagonist elagolix for the management of endometriosis-associated pain. Pain Manag. 2019 Sep;9(5):497–515. doi: 10.2217/pmt-2019-0010. PMID: 31434540.; Singh D, Beeh KM, Colgan B, Kornmann O, Leaker B, Watz H, Lucci G, Geraci S, Emirova A, Govoni M, Nandeuil MA. Effect of the inhaled PDE4 inhibitor CHF6001 on biomarkers of inflammation in COPD. Respiratory Research. 2019 Aug 09;20(1):180. doi: 10.1186/s12931-019-1142-7.; Barra F, Seca M, Della Corte L, Giampaolino P, Ferrero S. Relugolix for the treatment of uterine fibroids. Drugs Today (Barc). 2019 Aug;55(8):503–12. doi: 10.1358/dot.2019.55.8.3020179. PMID: 31461087.; Moehle MS, Conn PJ. Roles of the M₄ acetylcholine receptor in the basal ganglia and the treatment of movement disorders. Movement Disorders. 2019 Jun 18;34(8):1089–99. doi: 10.1002/mds.27740.; Ztaou S, Amalric M. Contribution of cholinergic interneurons to striatal pathophysiology in Parkinson's disease. Neurochem Int. 2019 Jun;126():1–10. doi: 10.1016/j.neuint.2019.02.019. PMID: 30825602.; Amato D, Kruyer A, Samaha AN, Heinz A. Hypofunctional Dopamine Uptake and Antipsychotic Treatment-Resistant Schizophrenia. Front Psychiatry. 2019;10():314. PMID: 31214054; PMCID: PMC6557273.; Kim SH, Riaposova L, Ahmed H, Pohl O, Chollet A, Gotteland J, Hanyaloglu A, Bennett PR, Terzidou V. Oxytocin Receptor Antagonists, Atosiban and Nolasiban, Inhibit Prostaglandin F2a-induced Contractions and Inflammatory Responses in Human Myometrium. Scientific Reports. 2019 Apr 08;9(1):5792. doi: 10.1038/s41598-019-42181-2.; Burghi V, Echeverría EB, Sosa MH, Quiroga DT, Muñoz MC, Davio C, Monczor F, Fernández NC, Dominici FP. Participation of Gai-Adenylate Cyclase and ERK1/2 in Mas Receptor Signaling Pathways. Front. Pharmacol. 2019 Feb 22;10(). doi: 10.3389/fphar.2019.00146.; Kragstrup TW, Adams M, Lomholt S, Nielsen MA, Heftdal LD, Schafer P, Deleuran B. IL-12/IL-23p40 identified as a downstream target of apremilast in ex vivo models of arthritis. Therapeutic Advances in Musculoskeletal. 2019 Jan;11(). doi: 10.1177/1759720x19828669.; An R, Liu J, He J, Wang F, Zhang Q, Yu Q. PDE3A inhibitor anagrelide activates death signaling pathway genes and synergizes with cell death-inducing cytokines to selectively inhibit cancer cell growth. Am J Cancer Res. 2019;9(9):1905–21. PMID: 31598394; PMCID: PMC6780660.; Wu M, Liang Y, Dai Z, Wang S. Perioperative dexmedetomidine reduces delirium after cardiac surgery: A meta-analysis of randomized controlled trials. Journal of Clinical Anesthesia. 2018 Nov;50():33–42. doi: 10.1016/j.jclinane.2018.06.045.; Flükiger J, Hollinger A, Speich B, Meier V, Tontsch J, Zehnder T, Siegemund M. Dexmedetomidine in prevention and treatment of postoperative and intensive care unit delirium: a systematic review and meta-analysis. Annals of Intensive Care. 2018 Sep 20;8(1):92. doi: 10.1186/s13613-018-0437-z.; Lamb YN. Elagolix: First Global Approval. Drugs. 2018 Sep 08;78(14):1501–8. doi: 10.1007/s40265-018-0977-4.; Poch E, Rodas L, Blasco M, Molina A, Quintana L. An update on tolvaptan for autosomal dominant polycystic kidney disease. Drugs Today (Barc). 2018 Sep;54(9):519–33. doi: 10.1358/dot.2018.54.9.2776624. PMID: 30303493.; Glaenzel U, Jin Y, Nufer R, Li W, Schroer K, Adam-Stitah S, Peter van Marle S, Legangneux E, Borell H, James AD, Meissner A, Camenisch G, Gardin A: Metabolism and Disposition of Siponimod, a Novel Selective S1P1/S1P5 Agonist, in Healthy Volunteers and In Vitro Identification of Human Cytochrome P450 Enzymes Involved in Its Oxidative Metabolism. Drug Metab Dispos. 2018 Jul;46(7):1001-1013. doi: 10.1124/dmd.117.079574. Epub 2018 May 7.; Surrey E, Taylor HS, Giudice L, Lessey BA, Abrao MS, Archer DF, Diamond MP, Johnson NP, Watts NB, Gallagher JC, Simon JA, Carr BR, Dmowski WP, Leyland N, Singh SS, Rechberger T, Agarwal SK, Duan WR, Schwefel B, Thomas JW, Peloso PM, Ng J, Soliman AM, Chwalisz K. Long-Term Outcomes of Elagolix in Women With Endometriosis: Results From Two Extension Studies. Obstet Gynecol. 2018 Jul;132(1):147–60. doi: 10.1097/aog.0000000000002675. PMID: 29889764.; Osland ST, Steeves TD, Pringsheim T. Pharmacological treatment for attention deficit hyperactivity disorder (ADHD) in children with comorbid tic disorders. Cochrane Database Syst Rev. 2018 Jun 26;6():CD007990. PMID: 29944175; PMCID: PMC6513283.; Ferrero S, Barra F, Leone Roberti Maggiore U. Current and Emerging Therapeutics for the Management of Endometriosis. Drugs. 2018 Jul;78(10):995–1012. doi: 10.1007/s40265-018-0928-0. PMID: 29946962.; Tran HDM, Tran YH, Tran TD, Jong M, Coroneo M, Sankaridurg P. A Review of Myopia Control with Atropine. Journal of Ocular Pharmacology and Therapeutics. 2018 Jun;34(5):374–9. doi: 10.1089/jop.2017.0144.; Yoshida M, Kakizaki H, Takahashi S, Nagai S, Kurose T. Long-term safety and efficacy of the novel ß ₃ -adrenoreceptor agonist vibegron in Japanese patients with overactive bladder: A phase III prospective study. Int J of Urology. 2018 May 11;25(7):668–75. doi: 10.1111/iju.13596.; Yoshida M, Takeda M, Gotoh M, Nagai S, Kurose T. Vibegron, a Novel Potent and Selective ß3-Adrenoreceptor Agonist, for the Treatment of Patients with Overactive Bladder: A Randomized, Double-blind, Placebo-controlled Phase 3 Study. Eur Urol. 2018 May;73(5):783–90. doi: 10.1016/j.eururo.2017.12.022. PMID: 29366513.; Edvinsson L. The CGRP Pathway in Migraine as a Viable Target for Therapies. Headache. 2018 May;58 Suppl 1():33–47. doi: 10.1111/head.13305. PMID: 29697153.; Gómez-Aguayo F, Paczka JA, Leñero-Córdova R, Jiménez-Román J, Davila-Villarreal J, Hartleben C, Baiza-Durán L, Olvera-Montaño O, García-Velez F, Muñoz-Villegas P. A Phase III Randomized Clinical Trial of a 0.5% Timolol + 0.2% Brimonidine + 2.0% Dorzolamide Fixed Combination, Preservative-Free Ophthalmic Solution vs. 0.5% Timolol + 0.2% Brimonidine + 2.0% Dorzolamide Fixed Combination in Patients with Controlled Primary Open-Angle Glaucoma. Ophthalmology and Therapy. 2018 Apr 21;7(1):145–56. doi: 10.1007/s40123-018-0128-8.; Kawata T, Tokunaga S, Murai M, Masuda N, Haruyama W, Shoukei Y, Hisada Y, Yanagida T, Miyazaki H, Wada M, Akizawa T, Fukagawa M. A novel calcimimetic agent, evocalcet (MT-4580/KHK7580), suppresses the parathyroid cell function with little effect on the gastrointestinal tract or CYP isozymes in vivo and in vitro. PLoS ONE. 2018 Apr 03;13(4):e0195316. doi: 10.1371/journal.pone.0195316.; Liu F, Yu H, Lin C, Elzoghby AO, Hwang T, Fang J. Use of cilomilast-loaded phosphatiosomes to suppress neutrophilic inflammation for attenuating acute lung injury: the effect of nanovesicular surface charge. Journal of Nanobiotechnology. 2018 Mar 30;16(1):35. doi: 10.1186/s12951-018-0364-z.; Skljarevski V, Oakes TM, Zhang Q, Ferguson MB, Martinez J, Camporeale A, Johnson KW, Shan Q, Carter J, Schacht A, Goadsby PJ, Dodick DW. Effect of Different Doses of Galcanezumab vs Placebo for Episodic Migraine Prevention: A Randomized Clinical Trial. JAMA Neurol. 2018 Feb 01;75(2):187–93. PMID: 29255900; PMCID: PMC5838630.; Liu DY, Wang ZG, Gao Y, Zhang HM, Zhang YX, Wang XJ, Peng D. Effect and safety of roflumilast for chronic obstructive pulmonary disease in Chinese patients. Medicine (Baltimore). 2018 Feb;97(7):e9864. PMID: 29443750; PMCID: PMC5839818.; Filardo EJ. A role for G-protein coupled estrogen receptor (GPER) in estrogen-induced carcinogenesis: Dysregulated glandular homeostasis, survival and metastasis. The Journal of Steroid Biochemistry and Molecular Biology. 2018 Feb;176():38–48. doi: 10.1016/j.jsbmb.2017.05.005.; Santos RAS, Sampaio WO, Alzamora AC, Motta-Santos D, Alenina N, Bader M, Campagnole-Santos MJ. The ACE2/Angiotensin-(1–7)/MAS Axis of the Renin-Angiotensin System: Focus on Angiotensin-(1–7). Physiological Reviews. 2018 Jan 01;98(1):505–53. doi: 10.1152/physrev.00023.2016.; Nazir M, Senkowski W, Nyberg F, Blom K, Edqvist PH, Jarvius M, Andersson C, Gustafsson MG, Nygren P, Larsson R, Fryknäs M. Targeting tumor cells based on Phosphodiesterase 3A expression. Exp Cell Res. 2017 Dec 15;361(2):308–15. doi: 10.1016/j.yexcr.2017.10.032. PMID: 29107068.; Silberstein SD, Dodick DW, Bigal ME, Yeung PP, Goadsby PJ, Blankenbiller T, Grozinski-Wolff M, Yang R, Ma Y, Aycardi E. Fremanezumab for the Preventive Treatment of Chronic Migraine. N Engl J Med. 2017 Nov 30;377(22):2113–22. doi: 10.1056/nejmoa1709038. PMID: 29171818.; Dubin A, Lattanzio B, Gatti L. The spectrum of cardiovascular effects of dobutamine - from healthy subjects to septic shock patients. Rev Bras Ter Intensiva. 2017 Oct;29(4):490–8. PMID: 29340539; PMCID: PMC5764562.; Beier J, Fuhr R, Seoane B, Massana E, de Miquel G, Pujol H, Ruiz S. Efficacy, safety, and tolerability of once-daily abediterol in patients with stable, persistent asthma: a Phase II, randomized, 7-day, crossover study. Pharmacology Res & Perspec. 2017 Sep 27;5(5). doi: 10.1002/prp2.356.; Gold LS, Papp K, Lynde C, Lain E, Gooderham M, Johnson S, Kerrouche N. Treatment of Rosacea With Concomitant Use of Topical Ivermectin 1% Cream and Brimonidine 0.33% Gel: A Randomized, Vehicle-controlled Study. J Drugs Dermatol. 2017 Sep 01;16(9):909–16. PMID: 28915286.; Kim M, Kim J, Jeong S, Jo H, Woo YR, Park HJ. Inhibition of mast cell infiltration in an LL-37-induced rosacea mouse model using topical brimonidine tartrate 0.33% gel. Experimental Dermatology. 2017 Aug 15;26(11):1143–5. doi: 10.1111/exd.13381.; Keeshin BR, Ding Q, Presson AP, Berkowitz SJ, Strawn JR. Use of Prazosin for Pediatric PTSD-Associated Nightmares and Sleep Disturbances: A Retrospective Chart Review. Neurology and Therapy. 2017 Jul 28;6(2):247–57. doi: 10.1007/s40120-017-0078-4.; Gonzalez de Valdivia E, Broselid S, Kahn R, Olde B, Leeb-Lundberg LMF. G protein-coupled estrogen receptor 1 (GPER1)/GPR30 increases ERK1/2 activity through PDZ motif-dependent and -independent mechanisms. Journal of Biological Chemistry. 2017 Jun;292(24):9932–43. doi: 10.1074/jbc.m116.765875.; Nguyen V, Tiemann D, Park E, Salehi A. Alpha-2 Agonists. Anesthesiol Clin. 2017 Jun;35(2):233–45. doi: 10.1016/j.anclin.2017.01.009. PMID: 28526145.; Wijemanne S, Vijayakumar D, Jankovic J. Apraclonidine in the treatment of ptosis. Journal of the Neurological Sciences. 2017 May;376():129–32. doi: 10.1016/j.jns.2017.03.025.; Baker JG, Gardiner SM, Woolard J, Fromont C, Jadhav GP, Mistry SN, Thompson KSJ, Kellam B, Hill SJ, Fischer PM. Novel selective ß ₁ -adrenoceptor antagonists for concomitant cardiovascular and respiratory disease. The FASEB Journal. 2017 Apr 11;31(7):3150–66. doi: 10.1096/fj.201601305r.; Westman PC, Lipinski MJ, Torguson R, Waksman R. A comparison of cangrelor, prasugrel, ticagrelor, and clopidogrel in patients undergoing percutaneous coronary intervention: A network meta-analysis. Cardiovascular Revascularization Medicine. 2017 Mar;18(2):79–85. doi: 10.1016/j.carrev.2016.10.005.; Kaufman PL: Latanoprostene bunod ophthalmic solution 0.024% for IOP lowering in glaucoma and ocular hypertension. Expert Opin Pharmacother. 2017 Mar;18(4):433-444. doi: 10.1080/14656566.2017.1293654. Epub 2017 Feb 20.; Di Salvo J, Nagabukuro H, Wickham LA, Abbadie C, DeMartino JA, Fitzmaurice A, Gichuru L, Kulick A, Donnelly MJ, Jochnowitz N, Hurley AL, Pereira A, Sanfiz A, Veronin G, Villa K, Woods J, Zamlynny B, Zycband E, Salituro GM, Frenkl T, Weber AE, Edmondson SD, Struthers M. Pharmacological Characterization of a Novel Beta 3 Adrenergic Agonist, Vibegron: Evaluation of Antimuscarinic Receptor Selectivity for Combination Therapy for Overactive Bladder. The Journal of Pharmacology and Experimental Therapeutics. 2017 Feb;360(2):346–55. doi: 10.1124/jpet.116.237313.; Alexander A, Irving AJ, Harvey J. Emerging roles for the novel estrogen-sensing receptor GPER1 in the CNS. Neuropharmacology. 2017 Feb;113(Pt B):652–60. doi: 10.1016/j.neuropharm.2016.07.003. PMID: 27392633.; Noronha Neto C C, Maia SSB, Katz L, Coutinho IC, Souza AR, Amorim MM. Clonidine versus Captopril for Severe Postpartum Hypertension: A Randomized Controlled Trial. PLoS ONE. 2017 Jan 26;12(1):e0168124. doi: 10.1371/journal.pone.0168124.; Vijayakumar D, Wijemanne S, Jankovic J. Treatment of blepharospasm with apraclonidine. Journal of the Neurological Sciences. 2017 Jan;372():57–9. doi: 10.1016/j.jns.2016.11.029.; Freire MO, Dalli J, Serhan CN, Van Dyke TE. Neutrophil Resolvin E1 Receptor Expression and Function in Type 2 Diabetes. J Immunol. 2017 Jan 15;198(2):718–28. PMID: 27994073; PMCID: PMC5224973.; Aungraheeta R, Conibear A, Butler M, Kelly E, Nylander S, Mumford A, Mundell SJ. Inverse agonism at the P2Y12 receptor and ENT1 transporter blockade contribute to platelet inhibition by ticagrelor. Blood. 2016 Dec 08;128(23):2717–28. PMID: 27694321; PMCID: PMC5161012.; Wangler NJ, Jayaraman S, Zhu R, Mechref Y, Abbruscato TJ, Bickel U, Karamyan VT. Preparation and preliminary characterization of recombinant neurolysin for in vivo studies. J Biotechnol. 2016 Sep 20;234():105–15. doi: 10.1016/j.jbiotec.2016.07.007. PMID: 27496565.; Bajracharya SR, Prasad PN, Ghimire R. Management of Organophosphorus Poisoning. J Nepal Health Res Counc. 2016 Sep;14(34):131–8. PMID: 28327676.; Beier J, Pujol H, Seoane B, Jimenez E, Astbury C, Massana E, Ruiz S, de Miquel G. Abediterol, a novel long-acting ß2-agonist: bronchodilation, safety, tolerability and pharmacokinetic results from a single-dose, dose-ranging, active-comparator study in patients with COPD. BMC Pulmonary Medicine. 2016 Jul 20;16(1):102. doi: 10.1186/s12890-016-0266-5.; Huang WL, Li Z, Lin TY, Wang SW, Wu FJ, Luo CW. Thyrostimulin-TSHR signaling promotes the proliferation of NIH:OVCAR-3 ovarian cancer cells via trans-regulation of the EGFR pathway. Sci Rep. 2016 Jun 07;6():27471. PMID: 27273257; PMCID: PMC4895341.; Bower RL, Hay DL. Amylin structure–function relationships and receptor pharmacology: implications for amylin mimetic drug development. British J Pharmacology. 2016 May 18;173(12):1883–98. doi: 10.1111/bph.13496.; Nederpelt I, Vergroesen RD, IJzerman AP, Heitman LH. Persistent GnRH receptor activation in pituitary aT3-1 cells analyzed with a label-free technology. Biosens Bioelectron. 2016 May 15;79():721–7. doi: 10.1016/j.bios.2015.12.066. PMID: 26774084.; Tran Q, Firkins R, Giles J, Francis S, Matnishian V, Tran P, VerMeer M, Jasurda J, Burgard MA, Gebert-Oberle B. Estrogen Enhances Linkage in the Vascular Endothelial Calmodulin Network via a Feedforward Mechanism at the G Protein-coupled Estrogen Receptor 1. Journal of Biological Chemistry. 2016 May;291(20):10805–23. doi: 10.1074/jbc.m115.697334.; Rutkowska A, O’Sullivan SA, Christen I, Zhang J, Sailer AW, Dev KK. The EBI2 signalling pathway plays a role in cellular crosstalk between astrocytes and macrophages. Scientific Reports. 2016 May 11;6(1):25520. doi: 10.1038/srep25520.; Alamo C, López-Muñoz F, Sánchez-García J. Mechanism of action of guanfacine: a postsynaptic differential approach to the treatment of attention deficit hyperactivity disorder (adhd). Actas Esp Psiquiatr. 2016 May;44(3):107–12. PMID: 27254403.; Al-Inany HG, Youssef MA, Ayeleke RO, Brown J, Lam WS, Broekmans FJ: Gonadotrophin-releasing hormone antagonists for assisted reproductive technology. Cochrane Database Syst Rev. 2016 Apr 29;4:CD001750. doi: 10.1002/14651858.CD001750.pub4.; Scott FL, Clemons B, Brooks J, Brahmachary E, Powell R, Dedman H, Desale HG, Timony GA, Martinborough E, Rosen H, Roberts E, Boehm MF, Peach RJ. Ozanimod (RPC1063) is a potent sphingosine-1-phosphate receptor-1 (S1P ₁ ) and receptor-5 (S1P ₅ ) agonist with autoimmune disease-modifying activity. British J Pharmacology. 2016 Apr 28;173(11):1778–92. doi: 10.1111/bph.13476.; Akizawa T, Kurita N, Mizobuchi M, Fukagawa M, Onishi Y, Yamaguchi T, Ellis AR, Fukuma S, Alan Brookhart M, Hasegawa T, Kurokawa K, Fukuhara S. PTH-dependence of the effectiveness of cinacalcet in hemodialysis patients with secondary hyperparathyroidism. Scientific Reports. 2016 Apr 13;6(1):19612. doi: 10.1038/srep19612.; Rapoport B, McLachlan SM. TSH Receptor Cleavage Into Subunits and Shedding of the A-Subunit; A Molecular and Clinical Perspective. Endocr Rev. 2016 Apr;37(2):114–34. PMID: 26799472; PMCID: PMC4823380.; Davenport AP, Hyndman KA, Dhaun N, Southan C, Kohan DE, Pollock JS, Pollock DM, Webb DJ, Maguire JJ. Endothelin. Pharmacological Reviews. 2016 Apr;68(2):357–418. doi: 10.1124/pr.115.011833.; Nylander S, Schulz R. Effects of P2Y₁₂ receptor antagonists beyond platelet inhibition – comparison of ticagrelor with thienopyridines. British J Pharmacology. 2016 Feb 24;173(7):1163–78. doi: 10.1111/bph.13429.; Edmondson SD, Zhu C, Kar NF, Di Salvo J, Nagabukuro H, Sacre-Salem B, Dingley K, Berger R, Goble SD, Morriello G, Harper B, Moyes CR, Shen DM, Wang L, Ball R, Fitzmaurice A, Frenkl T, Gichuru LN, Ha S, Hurley AL, Jochnowitz N, Levorse D, Mistry S, Miller RR, Ormes J, Salituro GM, Sanfiz A, Stevenson AS, Villa K, Zamlynny B, Green S, Struthers M, Weber AE. Discovery of Vibegron: A Potent and Selective ß3 Adrenergic Receptor Agonist for the Treatment of Overactive Bladder. J Med Chem. 2016 Jan 28;59(2):609–23. doi: 10.1021/acs.jmedchem.5b01372. PMID: 26709102.; Shi L, Lehto SG, Zhu DXD, Sun H, Zhang J, Smith BP, Immke DC, Wild KD, Xu C. Pharmacologic Characterization of AMG 334, a Potent and Selective Human Monoclonal Antibody against the Calcitonin Gene-Related Peptide Receptor. The Journal of Pharmacology and Experimental Therapeutics. 2016 Jan;356(1):223–31. doi: 10.1124/jpet.115.227793.; Gaudet HM, Cheng SB, Christensen EM, Filardo EJ. The G-protein coupled estrogen receptor, GPER: The inside and inside-out story. Mol Cell Endocrinol. 2015 Dec 15;418 Pt 3():207–19. doi: 10.1016/j.mce.2015.07.016. PMID: 26190834.; Alexander SP, Davenport AP, Kelly E, Marrion N, Peters JA, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Southan C, Davies JA; CGTP Collaborators. The Concise Guide to PHARMACOLOGY 2015/16: G protein-coupled receptors. Br J Pharmacol. 2015 Dec;172(24):5744–869. PMID: 26650439; PMCID: PMC4718210.; Nederpelt I, Georgi V, Schiele F, Nowak-Reppel K, Fernández-Montalván AE, IJzerman AP, Heitman LH. Characterization of 12 GnRH peptide agonists – a kinetic perspective. British J Pharmacology. 2015 Nov 04;173(1):128–41. doi: 10.1111/bph.13342.; Bigal ME, Dodick DW, Rapoport AM, Silberstein SD, Ma Y, Yang R, Loupe PS, Burstein R, Newman LC, Lipton RB. Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of high-frequency episodic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study. Lancet Neurol. 2015 Nov;14(11):1081–90. doi: 10.1016/s1474-4422(15)00249-5. PMID: 26432182.; Salhiyyah K, Forster R, Senanayake E, Abdel-Hadi M, Booth A, Michaels JA. Pentoxifylline for intermittent claudication. Cochrane Database Syst Rev. 2015 Sep 29;9():CD005262. PMID: 26417854; PMCID: PMC6513423.; Kauh CY, Bursztyn LL. Positive Apraclonidine Test in Horner Syndrome Caused by Thalamic Hemorrhage. J Neuroophthalmol. 2015 Sep;35(3):287–8. doi: 10.1097/wno.0000000000000222. PMID: 25768246.; Gelotte CK, Zimmerman BA. Pharmacokinetics, Safety, and Cardiovascular Tolerability of Phenylephrine HCl 10, 20, and 30 mg After a Single Oral Administration in Healthy Volunteers. Clinical Drug Investigation. 2015 Aug 13;35(9):547–58. doi: 10.1007/s40261-015-0311-9.; Tong GX, Mody K, Wang Z, Hamele-Bena D, Nikiforova MN, Nikiforov YE. Mutations of TSHR and TP53 Genes in an Aggressive Clear Cell Follicular Carcinoma of the Thyroid. Endocr Pathol. 2015 Dec;26(4):315–9. doi: 10.1007/s12022-015-9388-1. PMID: 26260781.; Paoletta S, Sabbadin D, von Kügelgen I, Hinz S, Katritch V, Hoffmann K, Abdelrahman A, Straßburger J, Baqi Y, Zhao Q, Stevens RC, Moro S, Müller CE, Jacobson KA. Modeling ligand recognition at the P2Y12 receptor in light of X-ray structural information. Journal of Computer-Aided Molecular Design. 2015 Jul 21;29(8):737–56. doi: 10.1007/s10822-015-9858-z.; Panula P, Chazot PL, Cowart M, Gutzmer R, Leurs R, Liu WLS, Stark H, Thurmond RL, Haas HL. International Union of Basic and Clinical Pharmacology. XCVIII. Histamine Receptors. Pharmacological Reviews. 2015 Jul;67(3):601–55. doi: 10.1124/pr.114.010249.; Sakai M, Martinez-Arguelles DB, Patterson NH, Chaurand P, Papadopoulos V. In Search of the Molecular Mechanisms Mediating the Inhibitory Effect of the GnRH Antagonist Degarelix on Human Prostate Cell Growth. PLoS ONE. 2015 Mar 26;10(3):e0120670. doi: 10.1371/journal.pone.0120670.; Golding JF, Gresty MA. Pathophysiology and treatment of motion sickness. Curr Opin Neurol. 2015 Feb;28(1):83–8. doi: 10.1097/wco.0000000000000163. PMID: 25502048.; He H, Li W, Liyanarachchi S, Jendrzejewski J, Srinivas M, Davuluri RV, Nagy R, de la Chapelle A. Genetic predisposition to papillary thyroid carcinoma: involvement of FOXE1, TSHR, and a novel lincRNA gene, PTCSC2. J Clin Endocrinol Metab. 2015 Jan;100(1):E164–72. PMID: 25303483; PMCID: PMC4283026.; William Tank A, Lee Wong D. Peripheral and Central Effects of Circulating Catecholamines. Comprehensive Physiology. 2015 Jan;5(1):1–15. doi: 10.1002/j.2040-4603.2015.tb00599.x.; Davari AS, Abnous K, Mehri S, Ghandadi M, Hadizadeh F. Synthesis and biological evaluation of novel pyridine derivatives as potential anticancer agents and phosphodiesterase-3 inhibitors. Bioorg Chem. 2014 Dec;57():83–9. doi: 10.1016/j.bioorg.2014.09.003. PMID: 25277835.; Dodick DW, Goadsby PJ, Silberstein SD, Lipton RB, Olesen J, Ashina M, Wilks K, Kudrow D, Kroll R, Kohrman B, Bargar R, Hirman J, Smith J; ALD403 study investigators. Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: a randomised, double-blind, placebo-controlled, exploratory phase 2 trial. Lancet Neurol. 2014 Nov;13(11):1100–7. doi: 10.1016/s1474-4422(14)70209-1. PMID: 25297013.; Currigan DA, Hughes RJ, Wright CE, Angus JA, Soeding PF. Vasoconstrictor responses to vasopressor agents in human pulmonary and radial arteries: an in vitro study. Anesthesiology. 2014 Nov;121(5):930–6. doi: 10.1097/aln.0000000000000430. PMID: 25198173.; Cernecka H, Sand C, Michel MC: The odd sibling: features of beta3-adrenoceptor pharmacology. Mol Pharmacol. 2014 Nov;86(5):479-84. doi: 10.1124/mol.114.092817. Epub 2014 Jun 2.; Mathur RP, Nayak S, Sivaramakrishnan R, Jain V. Role of Alpha Blockers in Hypertension with Benign Prostatic Hyperplasia. J Assoc Physicians India. 2014 Sep;62(9 Suppl):40–4. PMID: 26245042.; Broselid S, Berg KA, Chavera TA, Kahn R, Clarke WP, Olde B, Leeb-Lundberg LMF. G protein-coupled Receptor 30 (GPR30) Forms a Plasma Membrane Complex with Membrane-associated Guanylate Kinases (MAGUKs) and Protein Kinase A-anchoring Protein 5 (AKAP5) That Constitutively Inhibits cAMP Production. Journal of Biological Chemistry. 2014 Aug;289(32):22117–27. doi: 10.1074/jbc.m114.566893.; Ahn LY, Kim SE, Yi S, Dingemanse J, Lim KS, Jang I, Yu K. Pharmacokinetic–Pharmacodynamic Relationships of Macitentan, a New Endothelin Receptor Antagonist, After Multiple Dosing in Healthy Korean Subjects. American Journal of Cardiovascular Drugs. 2014 Jun 07;14(5):377–85. doi: 10.1007/s40256-014-0081-4.; Prossnitz ER, Barton M: Estrogen biology: new insights into GPER function and clinical opportunities. Mol Cell Endocrinol. 2014 May 25;389(1-2):71-83. doi: 10.1016/j.mce.2014.02.002. Epub 2014 Feb 12.; Liamis G, Filippatos TD, Elisaf MS. Treatment of hyponatremia: the role of lixivaptan. Expert Review of Clinical Pharmacology. 2014 Apr 28;7(4):431–41. doi: 10.1586/17512433.2014.911085.; Nadeau G, Schröder A, Moore K, Genois L, Lamontagne P, Hamel M, Pellerin E, Bolduc S. Long-term use of solifenacin in pediatric patients with overactive bladder: Extension of a prospective open-label study. Can Urol Assoc J. 2014 Mar;8(3-4):118–23. PMID: 24839481; PMCID: PMC4001633.; Ortega VE. Pharmacogenetics of beta2 adrenergic receptor agonists in asthma management. Clin Genet. 2014 Jul;86(1):12–20. doi: 10.1111/cge.12377. PMID: 24641588.; Maurice DH, Ke H, Ahmad F, Wang Y, Chung J, Manganiello VC. Advances in targeting cyclic nucleotide phosphodiesterases. Nature Reviews Drug Discovery. 2014 Apr 01;13(4):290–314. doi: 10.1038/nrd4228.; Blumer JB, Lanier SM. Activators of G Protein Signaling Exhibit Broad Functionality and Define a Distinct Core Signaling Triad. Molecular Pharmacology. 2014 Mar;85(3):388–96. doi: 10.1124/mol.113.090068.; Kubica J, Kozinski M, Navarese EP, Tantry U, Kubica A, Siller-Matula JM, Jeong Y, Fabiszak T, Andruszkiewicz A, Gurbel PA. Cangrelor: an emerging therapeutic option for patients with coronary artery disease. Current Medical Research and Opinion. 2014 Jan 24;30(5):813–28. doi: 10.1185/03007995.2014.880050.; Armstrong D, Summers C, Ewart L, Nylander S, Sidaway JE, van Giezen JJ. Characterization of the adenosine pharmacology of ticagrelor reveals therapeutically relevant inhibition of equilibrative nucleoside transporter 1. J Cardiovasc Pharmacol Ther. 2014 Mar;19(2):209–19. doi: 10.1177/1074248413511693. PMID: 24414167.; Alagha K, Palot A, Sofalvi T, Pahus L, Gouitaa M, Tummino C, Martinez S, Charpin D, Bourdin A, Chanez P. Long-acting muscarinic receptor antagonists for the treatment of chronic airway diseases. Therapeutic Advances in Chronic Disease. 2014 Jan 06;5(2):85–98. doi: 10.1177/2040622313518227.; Checler F. Experimental stroke: neurolysin back on stage. Journal of Neurochemistry. 2014 Jan 05;129(1):1–3. doi: 10.1111/jnc.12635.; Gingell JJ, Burns ER, Hay DL. Activity of pramlintide, rat and human amylin but not Aß1-42 at human amylin receptors. Endocrinology. 2014 Jan;155(1):21–6. doi: 10.1210/en.2013-1658. PMID: 24169554.; Hiroshima Y, Miyamoto H, Nakamura F, Masukawa D, Yamamoto T, Muraoka H, Kamiya M, Yamashita N, Suzuki T, Matsuzaki S, Endo I, Goshima Y. The protein Ocular albinism 1 is the orphan GPCR GPR143 and mediates depressor and bradycardic responses to DOPA in the nucleus tractus solitarii. British J Pharmacology. 2013 Dec 23;171(2):403–14. doi: 10.1111/bph.12459.; Rashid M, Wangler NJ, Yang L, Shah K, Arumugam TV, Abbruscato TJ, Karamyan VT. Functional up-regulation of endopeptidase neurolysin during post-acute and early recovery phases of experimental stroke in mouse brain. Journal of Neurochemistry. 2013 Nov 19;129(1):179–89. doi: 10.1111/jnc.12513.; Martin KJ, Bell G, Pickthorn K, Huang S, Vick A, Hodsman P, Peacock M: Velcalcetide (AMG 416), a novel peptide agonist of the calcium-sensing receptor, reduces serum parathyroid hormone and FGF23 levels in healthy male subjects. Nephrol Dial Transplant. 2014 Feb;29(2):385-92. doi: 10.1093/ndt/gft417. Epub 2013 Nov 13.; Ishizuka T, Yoshigae Y, Murayama N, Izumi T. Different hydrolases involved in bioactivation of prodrug-type angiotensin receptor blockers: carboxymethylenebutenolidase and carboxylesterase 1. Drug Metab Dispos. 2013 Nov;41(11):1888–95. doi: 10.1124/dmd.113.053595. PMID: 23946449.; Dauvilliers Y, Bassetti C, Lammers GJ, Arnulf I, Mayer G, Rodenbeck A, Lehert P, Ding CL, Lecomte JM, Schwartz JC; HARMONY I study group. Pitolisant versus placebo or modafinil in patients with narcolepsy: a double-blind, randomised trial. Lancet Neurol. 2013 Nov;12(11):1068–75. doi: 10.1016/s1474-4422(13)70225-4. PMID: 24107292.; Yoshiki H, Uwada J, Umada H, Kobayashi T, Takahashi T, Yamakawa T, Yamaguchi A, Yokoyama O, Muramatsu I. Agonist pharmacology at recombinant a_1A- and a_1L-adrenoceptors and in lower urinary tract a₁-adrenoceptors. British J Pharmacology. 2013 Oct 28;170(6):1242–52. doi: 10.1111/bph.12403.; Gialama F, Maniadakis N. Comprehensive overview: efficacy, tolerability, and cost-effectiveness of irbesartan. Vasc Health Risk Manag. 2013;9():575–92. PMID: 24124375; PMCID: PMC3794869.; Limonta P, Manea M. Gonadotropin-releasing hormone receptors as molecular therapeutic targets in prostate cancer: Current options and emerging strategies. Cancer Treat Rev. 2013 Oct;39(6):647–63. doi: 10.1016/j.ctrv.2012.12.003. PMID: 23290320.; Nylander S, Femia EA, Scavone M, Berntsson P, Asztély A-, Nelander K, Löfgren L, Nilsson RG, Cattaneo M. Ticagrelor inhibits human platelet aggregation via adenosine in addition to P2Y12 antagonism. Journal of Thrombosis and Haemostasis. 2013 Oct;11(10):1867–76. doi: 10.1111/jth.12360.; Andersson K, Martin N, Nitti V. Selective ß ₃ -Adrenoceptor Agonists for the Treatment of Overactive Bladder. Journal of Urology. 2013 Oct;190(4):1173–80. doi: 10.1016/j.juro.2013.02.104.; Walter S, Baruch A, Dong J, Tomlinson JE, Alexander ST, Janes J, Hunter T, Yin Q, Maclean D, Bell G, Mendel DB, Johnson RM, Karim F. Pharmacology of AMG 416 (Velcalcetide), a Novel Peptide Agonist of the Calcium-Sensing Receptor, for the Treatment of Secondary Hyperparathyroidism in Hemodialysis Patients. The Journal of Pharmacology and Experimental Therapeutics. 2013 Aug;346(2):229–40. doi: 10.1124/jpet.113.204834.; Sigterman KE, van Pinxteren B, Bonis PA, Lau J, Numans ME. Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease. Cochrane Database Syst Rev. 2013 May 31;(5):CD002095. PMID: 23728637; PMCID: PMC7066537.; Nitti VW, Khullar V, Kerrebroeck P, Herschorn S, Cambronero J, Angulo JC, Blauwet MB, Dorrepaal C, Siddiqui E, Martin NE. Mirabegron for the treatment of overactive bladder: a prespecified pooled efficacy analysis and pooled safety analysis of three randomised, double-blind, placebo-controlled, phase III studies. Int J Clin Pract. 2013 May 21;67(7):619–32. doi: 10.1111/ijcp.12194.; Meyer RC, Giddens MM, Schaefer SA, Hall RA. GPR37 and GPR37L1 are receptors for the neuroprotective and glioprotective factors prosaptide and prosaposin. Proc Natl Acad Sci U S A. 2013 Jun 04;110(23):9529–34. PMID: 23690594; PMCID: PMC3677493.; Lautner RQ, Villela DC, Fraga-Silva RA, Silva N, Verano-Braga T, Costa-Fraga F, Jankowski J, Jankowski V, Sousa F, Alzamora A, Soares E, Barbosa C, Kjeldsen F, Oliveira A, Braga J, Savergnini S, Maia G, Peluso AB, Passos-Silva D, Ferreira A, Alves F, Martins A, Raizada M, Paula R, Motta-Santos D, Klempin F, Kemplin F, Pimenta A, Alenina N, Sinisterra R, Bader M, Campagnole-Santos MJ, Santos RA. Discovery and characterization of alamandine: a novel component of the renin-angiotensin system. Circ Res. 2013 Apr 12;112(8):1104–11. doi: 10.1161/circresaha.113.301077. PMID: 23446738.; Roffler-Tarlov S, Liu JH, Naumova EN, Bernal-Ayala MM, Mason CA. L-Dopa and the Albino Riddle: Content of L-Dopa in the Developing Retina of Pigmented and Albino Mice. PLoS ONE. 2013 Mar 19;8(3):e57184. doi: 10.1371/journal.pone.0057184.; Pan S, Gray NS, Gao W, Mi Y, Fan Y, Wang X, Tuntland T, Che J, Lefebvre S, Chen Y, Chu A, Hinterding K, Gardin A, End P, Heining P, Bruns C, Cooke NG, Nuesslein-Hildesheim B: Discovery of BAF312 (Siponimod), a Potent and Selective S1P Receptor Modulator. ACS Med Chem Lett. 2013 Jan 4;4(3):333-7. doi: 10.1021/ml300396r. eCollection 2013 Mar 14.; Strauss U, Bräuer AU. Current views on regulation and function of plasticity-related genes (PRGs/LPPRs) in the brain. Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids. 2013 Jan;1831(1):133–8. doi: 10.1016/j.bbalip.2012.08.010.; Chang E, Ghosh N, Yanni D, Lee S, Alexandru D, Mozaffar T: A Review of Spasticity Treatments: Pharmacological and Interventional Approaches. Crit Rev Phys Rehabil Med. 2013;25(1-2):11-22. doi: 10.1615/CritRevPhysRehabilMed.2013007945.; EVOLVE Trial Investigators, Chertow GM, Block GA, Correa-Rotter R, Drüeke TB, Floege J, Goodman WG, Herzog CA, Kubo Y, London GM, Mahaffey KW, Mix TC, Moe SM, Trotman ML, Wheeler DC, Parfrey PS. Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. N Engl J Med. 2012 Dec 27;367(26):2482–94. doi: 10.1056/nejmoa1205624. PMID: 23121374.; Graham GJ, Locati M. Regulation of the immune and inflammatory responses by the 'atypical' chemokine receptor D6. The Journal of Pathology. 2012 Dec 12;229(2):168–75. doi: 10.1002/path.4123.; Luo G, Chen L, Conway CM, Denton R, Keavy D, Signor L, Kostich W, Lentz KA, Santone KS, Schartman R, Browning M, Tong G, Houston JG, Dubowchik GM, Macor JE. Discovery of (5S,6S,9R)-5-Amino-6-(2,3-difluorophenyl)-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridin-9-yl 4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxylate (BMS-927711): An Oral Calcitonin Gene-Related Peptide (CGRP) Antagonist in Clinical Trials for Treating Migraine. J. Med. Chem. 2012 Nov 15;55(23):10644–51. doi: 10.1021/jm3013147.; Cassio A, Nicoletti A, Rizzello A, Zazzetta E, Bal M, Baldazzi L. Current loss-of-function mutations in the thyrotropin receptor gene: when to investigate, clinical effects, and treatment. J Clin Res Pediatr Endocrinol. 2013;5 Suppl 1():29–39. PMID: 23154162; PMCID: PMC3608004.; Aparici M, Gómez-Angelats M, Vilella D, Otal R, Carcasona C, Viñals M, Ramos I, Gavaldà A, De Alba J, Gras J, Cortijo J, Morcillo E, Puig C, Ryder H, Beleta J, Miralpeix M. Pharmacological Characterization of Abediterol, a Novel Inhaled ß2-Adrenoceptor Agonist with Long Duration of Action and a Favorable Safety Profile in Preclinical Models. The Journal of Pharmacology and Experimental Therapeutics. 2012 Aug;342(2):497–509. doi: 10.1124/jpet.112.193284.; Filardo EJ, Thomas P. Minireview: G protein-coupled estrogen receptor-1, GPER-1: its mechanism of action and role in female reproductive cancer, renal and vascular physiology. Endocrinology. 2012 Jul;153(7):2953–62. PMID: 22495674; PMCID: PMC3380306.; Yanai K, Rogala B, Chugh K, Paraskakis E, Pampura AN, Boev R. Safety considerations in the management of allergic diseases: focus on antihistamines. Current Medical Research and Opinion. 2012 Mar 29;28(4):623–42. doi: 10.1185/03007995.2012.672405.; Moroni F, Cozzi A, Sili M, Mannaioni G. Kynurenic acid: a metabolite with multiple actions and multiple targets in brain and periphery. J Neural Transm (Vienna). 2012 Feb;119(2):133–9. doi: 10.1007/s00702-011-0763-x. PMID: 22215208.; Gras J. Mirabegron for the treatment of overactive bladder. Drugs Today (Barc). 2012 Jan;48(1):25–32. doi: 10.1358/dot.2012.48.1.1738056. PMID: 22384458.; Harvey RD. Muscarinic receptor agonists and antagonists: effects on cardiovascular function. Handb Exp Pharmacol. 2012;(208):299–316. doi: 10.1007/978-3-642-23274-9_13. PMID: 22222704.; Ehlert FJ, Pak KJ, Griffin MT. Muscarinic agonists and antagonists: effects on gastrointestinal function. Handb Exp Pharmacol. 2012;(208):343–74. doi: 10.1007/978-3-642-23274-9_15. PMID: 22222706.; Boyd KN, Mailman RB. Dopamine receptor signaling and current and future antipsychotic drugs. Handb Exp Pharmacol. 2012;(212):53–86. PMID: 23129328; PMCID: PMC4711768.; Jensen BC, O'Connell TD, Simpson PC. Alpha-1-adrenergic receptors: Targets for agonist drugs to treat heart failure. Journal of Molecular and Cellular Cardiology. 2011 Oct;51(4):518–28. doi: 10.1016/j.yjmcc.2010.11.014.; Guo Y, Zhang W, Giroux C, Cai Y, Ekambaram P, Dilly A, Hsu A, Zhou S, Maddipati KR, Liu J, Joshi S, Tucker SC, Lee M, Honn KV. Identification of the Orphan G Protein-coupled Receptor GPR31 as a Receptor for 12-(S)-Hydroxyeicosatetraenoic Acid. Journal of Biological Chemistry. 2011 Sep;286(39):33832–40. doi: 10.1074/jbc.m110.216564.; Krauss AHP, Impagnatiello F, Toris CB, Gale DC, Prasanna G, Borghi V, Chiroli V, Chong WKM, Carreiro ST, Ongini E. Ocular hypotensive activity of BOL-303259-X, a nitric oxide donating Prostaglandin F2a agonist, in preclinical models. Experimental Eye Research. 2011 Sep;93(3):250–5. doi: 10.1016/j.exer.2011.03.001.; Prossnitz ER, Barton M. The G-protein-coupled estrogen receptor GPER in health and disease. Nature Reviews Endocrinology. 2011 Aug 16;7(12):715–26. doi: 10.1038/nrendo.2011.122.; Nobles KN, Xiao K, Ahn S, Shukla AK, Lam CM, Rajagopal S, Strachan RT, Huang T, Bressler EA, Hara MR, Shenoy SK, Gygi SP, Lefkowitz RJ. Distinct Phosphorylation Sites on the ß ₂ -Adrenergic Receptor Establish a Barcode That Encodes Differential Functions of ß-Arrestin. Sci. Signal. 2011 Aug 09;4(185). doi: 10.1126/scisignal.2001707.; Hannedouche S, Zhang J, Yi T, Shen W, Nguyen D, Pereira JP, Guerini D, Baumgarten BU, Roggo S, Wen B, Knochenmuss R, Noël S, Gessier F, Kelly LM, Vanek M, Laurent S, Preuss I, Miault C, Christen I, Karuna R, Li W, Koo DI, Suply T, Schmedt C, Peters EC, Falchetto R, Katopodis A, Spanka C, Roy MO, Detheux M, Chen YA, Schultz PG, Cho CY, Seuwen K, Cyster JG, Sailer AW. Oxysterols direct immune cell migration via EBI2. Nature. 2011 Jul 27;475(7357):524–7. PMID: 21796212; PMCID: PMC4297623.; Gomez R, Por ED, Berg KA, Clarke WP, Glucksman MJ, Jeske NA. Metallopeptidase inhibition potentiates bradykinin-induced hyperalgesia. Pain. 2011 Jul;152(7):1548–54. PMID: 21458920; PMCID: PMC3114295.; Miwa K, Hitaka T, Imada T, Sasaki S, Yoshimatsu M, Kusaka M, Tanaka A, Nakata D, Furuya S, Endo S, Hamamura K, Kitazaki T: Discovery of 1-{4-[1-(2,6-difluorobenzyl)-5-[(dimethylamino)methyl]-3-(6-methoxypyridazin-3-yl )-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl]phenyl}-3-methoxyurea (TAK-385) as a potent, orally active, non-peptide antagonist of the human gonadotropin-releasing hormone receptor. J Med Chem. 2011 Jul 28;54(14):4998-5012. doi: 10.1021/jm200216q. Epub 2011 Jun 23.; Kinnamon SC. Taste receptor signalling – from tongues to lungs. Acta Physiologica. 2011 May 07;204(2):158–68. doi: 10.1111/j.1748-1716.2011.02308.x.; Bang-Andersen B, Ruhland T, Jorgensen M, Smith G, Frederiksen K, Jensen KG, Zhong H, Nielsen SM, Hogg S, Mork A, Stensbol TB: Discovery of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): a novel multimodal compound for the treatment of major depressive disorder. J Med Chem. 2011 May 12;54(9):3206-21. doi: 10.1021/jm101459g. Epub 2011 Apr 12.; Zhenfeng Zheng, Huilan Shi, Junya Jia, Dong Li, Shan Lin. A systematic review and meta-analysis of candesartan and losartan in the management of essential hypertension. J Renin Angiotensin Aldosterone Syst. 2011 Sep;12(3):365–74. doi: 10.1177/1470320310391503. PMID: 21421652.; Cambron M, Maertens H, Crevits L. Apraclonidine and my pupil. Clinical Autonomic Research. 2011 Mar 08;21(5):347–51. doi: 10.1007/s10286-011-0118-6.; Bhadada SV, Patel BM, Mehta AA, Goyal RK. ß₃Receptors: role in cardiometabolic disorders. Therapeutic Advances in Endocrinology. 2011 Feb 18;2(2):65–79. doi: 10.1177/2042018810390259.; Yamazaki T, Anraku T, Matsuzawa S: Ibudilast, a mixed PDE3/4 inhibitor, causes a selective and nitric oxide/cGMP-independent relaxation of the intracranial vertebrobasilar artery. Eur J Pharmacol. 2011 Jan 15;650(2-3):605-11. doi: 10.1016/j.ejphar.2010.10.033. Epub 2010 Oct 29.; Pal K, Swaminathan K, Xu HE, Pioszak AA. Structural Basis for Hormone Recognition by the Human CRFR2a G Protein-coupled Receptor. Journal of Biological Chemistry. 2010 Dec;285(51):40351–61. doi: 10.1074/jbc.m110.186072.; Raggi P, Chertow GM, Torres PU, Csiky B, Naso A, Nossuli K, Moustafa M, Goodman WG, Lopez N, Downey G, Dehmel B, Floege J; ADVANCE Study Group. The ADVANCE study: a randomized study to evaluate the effects of cinacalcet plus low-dose vitamin D on vascular calcification in patients on hemodialysis. Nephrol Dial Transplant. 2011 Apr;26(4):1327–39. doi: 10.1093/ndt/gfq725. PMID: 21148030.; Abraham WT, Aranda JM, Boehmer JP, Elkayam U, Gilbert EM, Gottlieb SS, Hasenfuß G, Kukin M, Lowes BD, O’Connell JB, Tavazzi L, Feldman AM, Ticho B, Orlandi C. Rationale and Design of the Treatment of Hyponatremia Based on Lixivaptan in NYHA Class III/IV Cardiac Patient Evaluation (THE BALANCE) Study. Clinical Translational Sci. 2010 Oct;3(5):249–53. doi: 10.1111/j.1752-8062.2010.00217.x.; Feary JR, Rodrigues LC, Smith CJ, Hubbard RB, Gibson JE. Prevalence of major comorbidities in subjects with COPD and incidence of myocardial infarction and stroke: a comprehensive analysis using data from primary care. Thorax. 2010 Nov;65(11):956–62. doi: 10.1136/thx.2009.128082. PMID: 20871122.; Oh DY, Talukdar S, Bae EJ, Imamura T, Morinaga H, Fan W, Li P, Lu WJ, Watkins SM, Olefsky JM. GPR120 is an omega-3 fatty acid receptor mediating potent anti-inflammatory and insulin-sensitizing effects. Cell. 2010 Sep 03;142(5):687–98. PMID: 20813258; PMCID: PMC2956412.; Chan KY, Edvinsson L, Eftekhari S, Kimblad PO, Kane SA, Lynch J, Hargreaves RJ, de Vries R, Garrelds IM, van den Bogaerdt AJ, Danser AHJ, MaassenVanDenBrink A. Characterization of the Calcitonin Gene-Related Peptide Receptor Antagonist Telcagepant (MK-0974) in Human Isolated Coronary Arteries. The Journal of Pharmacology and Experimental Therapeutics. 2010 Sep;334(3):746–52. doi: 10.1124/jpet.110.165993.; Block GA, Zaun D, Smits G, Persky M, Brillhart S, Nieman K, Liu J, St Peter WL. Cinacalcet hydrochloride treatment significantly improves all-cause and cardiovascular survival in a large cohort of hemodialysis patients. Kidney Int. 2010 Sep;78(6):578–89. doi: 10.1038/ki.2010.167. PMID: 20555319.; Hatzelmann A, Morcillo EJ, Lungarella G, Adnot S, Sanjar S, Beume R, Schudt C, Tenor H. The preclinical pharmacology of roflumilast – A selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease. Pulmonary Pharmacology & Therapeutics. 2010 Aug;23(4):235–56. doi: 10.1016/j.pupt.2010.03.011.; Thomas P, Alyea R, Pang Y, Peyton C, Dong J, Berg AH. Conserved estrogen binding and signaling functions of the G protein-coupled estrogen receptor 1 (GPER) in mammals and fish. Steroids. 2010 Aug;75(8-9):595–602. doi: 10.1016/j.steroids.2009.11.005.; Ohno Y. New insight into the therapeutic role of 5-HT1A receptors in central nervous system disorders. Cent Nerv Syst Agents Med Chem. 2010 Jun 01;10(2):148–57. doi: 10.2174/187152410791196341. PMID: 20518729.; Kong RCK, Shilling PJ, Lobb DK, Gooley PR, Bathgate RAD. Membrane receptors: Structure and function of the relaxin family peptide receptors. Molecular and Cellular Endocrinology. 2010 May;320(1-2):1–15. doi: 10.1016/j.mce.2010.02.003.; Sanu O, Lamont RF. Critical appraisal and clinical utility of atosiban in the management of preterm labor. Ther Clin Risk Manag. 2010 Apr 26;6():191–9. PMID: 20463780; PMCID: PMC2861440.; Seeman P. Dopamine D2 Receptors as Treatment Targets in Schizophrenia. Clinical Schizophrenia & Related Psychoses. 2010 Apr;4(1):56–73. doi: 10.3371/csrp.4.1.5.; Stahl SM. Mechanism of action of alpha 2A-adrenergic agonists in attention-deficit/hyperactivity disorder with or without oppositional symptoms. J Clin Psychiatry. 2010 Mar;71(3):223–4. doi: 10.4088/jcp.09bs05899pur. PMID: 20331927.; Leick M, Catusse J, Follo M, Nibbs RJ, Hartmann TN, Veelken H, Burger M. CCL19 is a specific ligand of the constitutively recycling atypical human chemokine receptor CRAM-B. Immunology. 2010 Mar 10;129(4):536–46. doi: 10.1111/j.1365-2567.2009.03209.x.; Chun J, Hartung HP. Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis. Clin Neuropharmacol. 2010 Mar;33(2):91–101. PMID: 20061941; PMCID: PMC2859693.; Ohira T, Arita M, Omori K, Recchiuti A, Van Dyke TE, Serhan CN. Resolvin E1 Receptor Activation Signals Phosphorylation and Phagocytosis. Journal of Biological Chemistry. 2010 Jan;285(5):3451–61. doi: 10.1074/jbc.m109.044131.; Van Poppel H. Evaluation of degarelix in the management of prostate cancer. Cancer Manag Res. 2010 Jan 25;2():39–52. PMID: 21188095; PMCID: PMC3004563.; Schemann M, Hafsi N, Michel K, Kober OI, Wollmann J, Li Q, Zeller F, Langer R, Lee K, Cellek S. The beta3-adrenoceptor agonist GW427353 (Solabegron) decreases excitability of human enteric neurons via release of somatostatin. Gastroenterology. 2010 Jan;138(1):266–74. doi: 10.1053/j.gastro.2009.09.046. PMID: 19786030.; Nijmeijer S, Leurs R, Vischer HF. Constitutive activity of the histamine H(1) receptor. Methods Enzymol. 2010;484():127–47. doi: 10.1016/b978-0-12-381298-8.00007-1. PMID: 21036230.; Meyerhof W, Batram C, Kuhn C, Brockhoff A, Chudoba E, Bufe B, Appendino G, Behrens M. The molecular receptive ranges of human TAS2R bitter taste receptors. Chem Senses. 2010 Feb;35(2):157–70. doi: 10.1093/chemse/bjp092. PMID: 20022913.; Konstam MA, Neaton JD, Dickstein K, Drexler H, Komajda M, Martinez FA, Riegger GA, Malbecq W, Smith RD, Guptha S, Poole-Wilson PA; HEAAL Investigators. Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial. Lancet. 2009 Nov 28;374(9704):1840–8. doi: 10.1016/s0140-6736(09)61913-9. PMID: 19922995.; Rolan P, Hutchinson M, Johnson K. Ibudilast: a review of its pharmacology, efficacy and safety in respiratory and neurological disease. Expert Opin Pharmacother. 2009 Dec;10(17):2897–904. doi: 10.1517/14656560903426189. PMID: 19929708.; Jensen BC, Swigart PM, De Marco T, Hoopes C, Simpson PC: {alpha}1-Adrenergic receptor subtypes in nonfailing and failing human myocardium. Circ Heart Fail. 2009 Nov;2(6):654-63. doi: 10.1161/CIRCHEARTFAILURE.108.846212. Epub 2009 Aug 6.; Ding Q, Gros R, Limbird LE, Chorazyczewski J, Feldman RD. Estradiol-mediated ERK phosphorylation and apoptosis in vascular smooth muscle cells requires GPR 30. American Journal of Physiology-Cell Physiology. 2009 Nov;297(5):C1178–87. doi: 10.1152/ajpcell.00185.2009.; Nazarian R, Weinberg JM. AN-2728, a PDE4 inhibitor for the potential topical treatment of psoriasis and atopic dermatitis. Curr Opin Investig Drugs. 2009 Nov;10(11):1236–42. PMID: 19876791.; Van Lith LH, Oosterom J, Van Elsas A, Zaman GJ. C5a-stimulated recruitment of beta-arrestin2 to the nonsignaling 7-transmembrane decoy receptor C5L2. J Biomol Screen. 2009 Oct;14(9):1067–75. doi: 10.1177/1087057109341407. PMID: 19641221.; Jensen BC, Swigart PM, Laden M, DeMarco T, Hoopes C, Simpson PC. The Alpha-1D Is the Predominant Alpha-1-Adrenergic Receptor Subtype in Human Epicardial Coronary Arteries. Journal of the American College of Cardiology. 2009 Sep;54(13):1137–45. doi: 10.1016/j.jacc.2009.05.056.; VAN GIEZEN JJJ, NILSSON L, BERNTSSON P, WISSING BM, GIORDANETTO F, TOMLINSON W, GREASLEY PJ. Ticagrelor binds to human P2Y12 independently from ADP but antagonizes ADP-induced receptor signaling and platelet aggregation. Journal of Thrombosis and Haemostasis. 2009 Sep;7(9):1556–65. doi: 10.1111/j.1538-7836.2009.03527.x.; Klos A, Tenner AJ, Johswich K, Ager RR, Reis ES, Köhl J. The role of the anaphylatoxins in health and disease. Molecular Immunology. 2009 Sep;46(14):2753–66. doi: 10.1016/j.molimm.2009.04.027.; Ahmed K, Tunaru S, Langhans C, Hanson J, Michalski CW, Kölker S, Jones PM, Okun JG, Offermanns S. Deorphanization of GPR109B as a Receptor for the ß-Oxidation Intermediate 3-OH-octanoic Acid and Its Role in the Regulation of Lipolysis. Journal of Biological Chemistry. 2009 Aug;284(33):21928–33. doi: 10.1074/jbc.m109.019455.; Quinn JA, Graeber CT, Frackelton AR, Kim M, Schwarzbauer JE, Filardo EJ. Coordinate regulation of estrogen-mediated fibronectin matrix assembly and epidermal growth factor receptor transactivation by the G protein-coupled receptor, GPR30. Mol Endocrinol. 2009 Jul;23(7):1052–64. PMID: 19342448; PMCID: PMC2703602.; Peng Q, Li K, Sacks SH, Zhou W. The role of anaphylatoxins C3a and C5a in regulating innate and adaptive immune responses. Inflamm Allergy Drug Targets. 2009 Jul;8(3):236–46. doi: 10.2174/187152809788681038. PMID: 19601884.; Fricks IP, Carter RL, Lazarowski ER, Harden TK. Gi-Dependent Cell Signaling Responses of the Human P2Y14 Receptor in Model Cell Systems. The Journal of Pharmacology and Experimental Therapeutics. 2009 Jul;330(1):162–8. doi: 10.1124/jpet.109.150730.; Williams JR, Khandoga AL, Goyal P, Fells JI, Perygin DH, Siess W, Parrill AL, Tigyi G, Fujiwara Y. Unique Ligand Selectivity of the GPR92/LPA5 Lysophosphatidate Receptor Indicates Role in Human Platelet Activation. Journal of Biological Chemistry. 2009 Jun;284(25):17304–19. doi: 10.1074/jbc.m109.003194.; Dawson LA, Watson JM. Vilazodone: A 5-HT_1AReceptor Agonist/Serotonin Transporter Inhibitor for the Treatment of Affective Disorders. CNS Neuroscience & Therapeutics. 2009 May 06;15(2):107–17. doi: 10.1111/j.1755-5949.2008.00067.x.; Hakak Y, Lehmann-Bruinsma K, Phillips S, Le T, Liaw C, Connolly DT, Behan DP. The role of the GPR91 ligand succinate in hematopoiesis. J Leukoc Biol. 2009 May;85(5):837–43. doi: 10.1189/jlb.1008618. PMID: 19204147.; Liu C, Wu J, Zhu J, Kuei C, Yu J, Shelton J, Sutton SW, Li X, Yun SJ, Mirzadegan T, Mazur C, Kamme F, Lovenberg TW. Lactate Inhibits Lipolysis in Fat Cells through Activation of an Orphan G-protein-coupled Receptor, GPR81. Journal of Biological Chemistry. 2009 Jan;284(5):2811–22. doi: 10.1074/jbc.m806409200.; Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet. 2009 Jan 03;373(9657):31–41. doi: 10.1016/s0140-6736(08)61764-x. PMID: 19058842.; Cai T, Ren N, Jin L, Cheng K, Kash S, Chen R, Wright SD, Taggart AKP, Waters MG. Role of GPR81 in lactate-mediated reduction of adipose lipolysis. Biochemical and Biophysical Research Communications. 2008 Dec;377(3):987–91. doi: 10.1016/j.bbrc.2008.10.088.; Rennard S, Knobil K, Rabe KF, Morris A, Schachter N, Locantore N, Canonica WG, Zhu Y, Barnhart F. The efficacy and safety of cilomilast in COPD. Drugs. 2008;68 Suppl 2():3–57. doi: 10.2165/0003495-200868002-00002. PMID: 19105585.; Pioszak AA, Parker NR, Suino-Powell K, Xu HE. Molecular Recognition of Corticotropin-releasing Factor by Its G-protein-coupled Receptor CRFR1. Journal of Biological Chemistry. 2008 Nov;283(47):32900–12. doi: 10.1074/jbc.m805749200.; Chen C, Wu D, Guo Z, Xie Q, Reinhart GJ, Madan A, Wen J, Chen T, Huang CQ, Chen M, Chen Y, Tucci FC, Rowbottom M, Pontillo J, Zhu YF, Wade W, Saunders J, Bozigian H, Struthers RS. Discovery of sodium R-(+)-4-{2-[5-(2-fluoro-3-methoxyphenyl)-3-(2-fluoro-6-[trifluoromethyl]benzyl)-4-methyl-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl]-1-phenylethylamino}butyrate (elagolix), a potent and orally available nonpeptide antagonist of the human gonadotropin-releasing hormone receptor. J Med Chem. 2008 Dec 11;51(23):7478–85. doi: 10.1021/jm8006454. PMID: 19006286.; Edelman S, Maier H, Wilhelm K. Pramlintide in the treatment of diabetes mellitus. BioDrugs. 2008;22(6):375–86. doi: 10.2165/0063030-200822060-00004. PMID: 18998755.; Oka S, Toshida T, Maruyama K, Nakajima K, Yamashita A, Sugiura T. 2-Arachidonoyl-sn-glycero-3-phosphoinositol: A Possible Natural Ligand for GPR55. Journal of Biochemistry. 2008 Oct 25;145(1):13–20. doi: 10.1093/jb/mvn136.; Lopez VM, Decatur CL, Stamer WD, Lynch RM, McKay BS. L-DOPA Is an Endogenous Ligand for OA1. PLoS Biol. 2008 Sep 30;6(9):e236. doi: 10.1371/journal.pbio.0060236.; Sears MR, Ottosson A, Radner F, Suissa S. Long-acting beta-agonists: a review of formoterol safety data from asthma clinical trials. Eur Respir J. 2009 Jan;33(1):21–32. doi: 10.1183/09031936.00145006. PMID: 18768573.; Murakami M, Shiraishi A, Tabata K, Fujita N. Identification of the orphan GPCR, P2Y10 receptor as the sphingosine-1-phosphate and lysophosphatidic acid receptor. Biochemical and Biophysical Research Communications. 2008 Jul;371(4):707–12. doi: 10.1016/j.bbrc.2008.04.145.; Bonham C, Abbott C. Are second generation antipsychotics a distinct class? J Psychiatr Pract. 2008 Jul;14(4):225–31. PMID: 18664891; PMCID: PMC3632396.; Ginès P, Wong F, Watson H, Milutinovic S, del Arbol LR, Olteanu D; HypoCAT Study Investigators. Effects of satavaptan, a selective vasopressin V(2) receptor antagonist, on ascites and serum sodium in cirrhosis with hyponatremia: a randomized trial. Hepatology. 2008 Jul;48(1):204–13. doi: 10.1002/hep.22293. PMID: 18508290.; Storjohann L, Holst B, Schwartz TW. Molecular mechanism of Zn2+ agonism in the extracellular domain of GPR39. FEBS Lett. 2008 Jul 23;582(17):2583–8. doi: 10.1016/j.febslet.2008.06.030. PMID: 18588883.; Lambert NA. Dissociation of heterotrimeric g proteins in cells. Sci Signal. 2008 Jun 24;1(25):re5. doi: 10.1126/scisignal.125re5. PMID: 18577758.; Otto C, Rohde-Schulz B, Schwarz G, Fuchs I, Klewer M, Brittain D, Langer G, Bader B, Prelle K, Nubbemeyer R, Fritzemeier KH. G protein-coupled receptor 30 localizes to the endoplasmic reticulum and is not activated by estradiol. Endocrinology. 2008 Oct;149(10):4846–56. doi: 10.1210/en.2008-0269. PMID: 18566127.; Fahed S, Grum DF, Papadimos TJ. Labetalol infusion for refractory hypertension causing severe hypotension and bradycardia: an issue of patient safety. Patient Safety in Surgery. 2008 May 27;2(1):13. doi: 10.1186/1754-9493-2-13.; Soundararajan M, Willard FS, Kimple AJ, Turnbull AP, Ball LJ, Schoch GA, Gileadi C, Fedorov OY, Dowler EF, Higman VA, Hutsell SQ, Sundström M, Doyle DA, Siderovski DP. Structural diversity in the RGS domain and its interaction with heterotrimeric G protein alpha-subunits. Proc Natl Acad Sci U S A. 2008 Apr 29;105(17):6457–62. PMID: 18434541; PMCID: PMC2359823.; Baker JG. A study of antagonist affinities for the human histamine H₂receptor. British J Pharmacology. 2008 Mar;153(5):1011–21. doi: 10.1038/sj.bjp.0707644.; Pasternack SM, von Kügelgen I, Al Aboud K, Lee YA, Rüschendorf F, Voss K, Hillmer AM, Molderings GJ, Franz T, Ramirez A, Nürnberg P, Nöthen MM, Betz RC. G protein-coupled receptor P2Y5 and its ligand LPA are involved in maintenance of human hair growth. Nat Genet. 2008 Mar;40(3):329–34. doi: 10.1038/ng.84. PMID: 18297070.; Oldham WM, Hamm HE. Heterotrimeric G protein activation by G-protein-coupled receptors. Nature Reviews Molecular Cell Biology. 2008 Jan;9(1):60–71. doi: 10.1038/nrm2299.; Kamen L, Henney HR, Runyan JD. A practical overview of tizanidine use for spasticity secondary to multiple sclerosis, stroke, and spinal cord injury. Current Medical Research and Opinion. 2007 Dec 31;24(2):425–39. doi: 10.1185/030079908x261113.; Ryberg E, Larsson N, Sjogren S, Hjorth S, Hermansson NO, Leonova J, Elebring T, Nilsson K, Drmota T, Greasley PJ: The orphan receptor GPR55 is a novel cannabinoid receptor. Br J Pharmacol. 2007 Dec;152(7):1092-101. doi: 10.1038/sj.bjp.0707460. Epub 2007 Sep 17.; Torricelli M, Giovannelli A, Leucci E, Florio P, De Falco G, Torres PB, Reis FM, Leoncini L, Petraglia F. Placental neurokinin B mRNA expression increases at preterm labor. Placenta. 2007 Oct;28(10):1020–3. doi: 10.1016/j.placenta.2007.04.006. PMID: 17561251.; Recober A, Russo AF. Olcegepant, a non-peptide CGRP1 antagonist for migraine treatment. IDrugs. 2007 Aug;10(8):566–74. PMID: 17665333.; Tobo M, Tomura H, Mogi C, Wang JQ, Liu JP, Komachi M, Damirin A, Kimura T, Murata N, Kurose H, Sato K, Okajima F. Previously postulated 'ligand-independent' signaling of GPR4 is mediated through proton-sensing mechanisms. Cell Signal. 2007 Aug;19(8):1745–53. doi: 10.1016/j.cellsig.2007.03.009. PMID: 17462861.; Filardo E, Quinn J, Pang Y, Graeber C, Shaw S, Dong J, Thomas P. Activation of the novel estrogen receptor G protein-coupled receptor 30 (GPR30) at the plasma membrane. Endocrinology. 2007 Jul;148(7):3236–45. doi: 10.1210/en.2006-1605. PMID: 17379646.; de Boer RA, Voors AA, van Veldhuisen DJ. Nebivolol: third-generation beta-blockade. Expert Opin Pharmacother. 2007 Jul;8(10):1539–50. doi: 10.1517/14656566.8.10.1539. PMID: 17661735.; Quaranta L, Turano R, Pizzolante T. Levobetaxolol hydrochloride: a review of its pharmacology and use in the treatment of chronic open-angle glaucoma and ocular hypertension. Clin Ophthalmol. 2007 Jun;1(2):93–7. PMID: 19668496; PMCID: PMC2704505.; Perez DM. Structure-function of alpha1-adrenergic receptors. Biochem Pharmacol. 2007 Apr 15;73(8):1051–62. PMID: 17052695; PMCID: PMC2034198.; Reese EA, Bunzow JR, Arttamangkul S, Sonders MS, Grandy DK. Trace Amine-Associated Receptor 1 Displays Species-Dependent Stereoselectivity for Isomers of Methamphetamine, Amphetamine, and Para-Hydroxyamphetamine. The Journal of Pharmacology and Experimental Therapeutics. 2007 Apr;321(1):178–86. doi: 10.1124/jpet.106.115402.; Ruiz-Gómez A, Molnar C, Holguín H, Mayor F, de Celis JF. The cell biology of Smo signalling and its relationships with GPCRs. Biochimica et Biophysica Acta (BBA) - Biomembranes. 2007 Apr;1768(4):901–12. doi: 10.1016/j.bbamem.2006.09.020.; Arita M, Ohira T, Sun YP, Elangovan S, Chiang N, Serhan CN. Resolvin E1 selectively interacts with leukotriene B4 receptor BLT1 and ChemR23 to regulate inflammation. J Immunol. 2007 Mar 15;178(6):3912–7. doi: 10.4049/jimmunol.178.6.3912. PMID: 17339491.; Halls ML, van der Westhuizen ET, Bathgate RAD, Summers RJ. Relaxin Family Peptide Receptors – former orphans reunite with their parent ligands to activate multiple signalling pathways. British J Pharmacology. 2007 Mar;150(6):677–91. doi: 10.1038/sj.bjp.0707140.; Lee CW, Rivera R, Dubin AE, Chun J. LPA(4)/GPR23 is a lysophosphatidic acid (LPA) receptor utilizing G(s)-, G(q)/G(i)-mediated calcium signaling and G(12/13)-mediated Rho activation. J Biol Chem. 2007 Feb 16;282(7):4310–7. doi: 10.1074/jbc.m610826200. PMID: 17166850.; Struthers RS, Xie Q, Sullivan SK, Reinhart GJ, Kohout TA, Zhu YF, Chen C, Liu XJ, Ling N, Yang W, Maki RA, Bonneville AK, Chen TK, Bozigian HP. Pharmacological characterization of a novel nonpeptide antagonist of the human gonadotropin-releasing hormone receptor, NBI-42902. Endocrinology. 2007 Feb;148(2):857–67. doi: 10.1210/en.2006-1213. PMID: 17095587.; Beeh KM, Derom E, Kanniess F, Cameron R, Higgins M, van As A. Indacaterol, a novel inhaled beta2-agonist, provides sustained 24-h bronchodilation in asthma. Eur Respir J. 2007 May;29(5):871–8. doi: 10.1183/09031936.00060006. PMID: 17251236.; Okamura N, Reinscheid RK. Neuropeptide S: a novel modulator of stress and arousal. Stress. 2007 Aug;10(3):221–6. doi: 10.1080/10253890701248673. PMID: 17613937.; Sampaio WO, Souza dos Santos RA, Faria-Silva R, da Mata Machado LT, Schiffrin EL, Touyz RM. Angiotensin-(1-7) through receptor Mas mediates endothelial nitric oxide synthase activation via Akt-dependent pathways. Hypertension. 2007 Jan;49(1):185–92. doi: 10.1161/01.hyp.0000251865.35728.2f. PMID: 17116756.; Holst B, Egerod KL, Schild E, Vickers SP, Cheetham S, Gerlach LO, Storjohann L, Stidsen CE, Jones R, Beck-Sickinger AG, Schwartz TW. GPR39 signaling is stimulated by zinc ions but not by obestatin. Endocrinology. 2007 Jan;148(1):13–20. doi: 10.1210/en.2006-0933. PMID: 16959833.; Ligneau X, Perrin D, Landais L, Camelin J-, Calmels TPG, Berrebi-Bertrand I, Lecomte J-, Parmentier R, Anaclet C, Lin J-, Bertaina-Anglade V, la Rochelle CD, d’Aniello F, Rouleau A, Gbahou F, Arrang J-, Ganellin CR, Stark H, Schunack W, Schwartz J-. BF2.649 [1-{3-[3-(4-Chlorophenyl)propoxy]propyl}piperidine, Hydrochloride], a Nonimidazole Inverse Agonist/Antagonist at the Human Histamine H3 Receptor: Preclinical Pharmacology. The Journal of Pharmacology and Experimental Therapeutics. 2007 Jan;320(1):365–75. doi: 10.1124/jpet.106.111039.; Boswell-Smith V, Spina D. PDE4 inhibitors as potential therapeutic agents in the treatment of COPD-focus on roflumilast. Int J Chron Obstruct Pulmon Dis. 2007;2(2):121–9. PMID: 18044684; PMCID: PMC2695611.; Johswich K, Martin M, Thalmann J, Rheinheimer C, Monk PN, Klos A. Ligand Specificity of the Anaphylatoxin C5L2 Receptor and Its Regulation on Myeloid and Epithelial Cell Lines. Journal of Biological Chemistry. 2006 Dec;281(51):39088–95. doi: 10.1074/jbc.m609734200.; Davis M, Maida V, Daeninck P, Pergolizzi J. The emerging role of cannabinoid neuromodulators in symptom management. Support Care Cancer. 2007 Jan;15(1):63–71. doi: 10.1007/s00520-006-0180-0. PMID: 17139494.; Migeotte I, Communi D, Parmentier M. Formyl peptide receptors: a promiscuous subfamily of G protein-coupled receptors controlling immune responses. Cytokine Growth Factor Rev. 2006 Dec;17(6):501–19. doi: 10.1016/j.cytogfr.2006.09.009. PMID: 17084101.; Schrier RW, Gross P, Gheorghiade M, Berl T, Verbalis JG, Czerwiec FS, Orlandi C; SALT Investigators. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med. 2006 Nov 16;355(20):2099–112. doi: 10.1056/nejmoa065181. PMID: 17105757.; Huang Z, Mancini JA. Phosphodiesterase 4 inhibitors for the treatment of asthma and COPD. Curr Med Chem. 2006;13(27):3253–62. doi: 10.2174/092986706778773040. PMID: 17168849.; Soupart A, Gross P, Legros JJ, Alföldi S, Annane D, Heshmati HM, Decaux G. Successful long-term treatment of hyponatremia in syndrome of inappropriate antidiuretic hormone secretion with satavaptan (SR121463B), an orally active nonpeptide vasopressin V2-receptor antagonist. Clin J Am Soc Nephrol. 2006 Nov;1(6):1154–60. doi: 10.2215/cjn.00160106. PMID: 17699341.; Ciana P, Fumagalli M, Trincavelli ML, Verderio C, Rosa P, Lecca D, Ferrario S, Parravicini C, Capra V, Gelosa P, Guerrini U, Belcredito S, Cimino M, Sironi L, Tremoli E, Rovati GE, Martini C, Abbracchio MP. The orphan receptor GPR17 identified as a new dual uracil nucleotides/cysteinyl-leukotrienes receptor. EMBO J. 2006 Oct 04;25(19):4615–27. PMID: 16990797; PMCID: PMC1589991.; Pedram A, Razandi M, Levin ER. Nature of functional estrogen receptors at the plasma membrane. Mol Endocrinol. 2006 Sep;20(9):1996–2009. doi: 10.1210/me.2005-0525. PMID: 16645038.; Kohno M, Hasegawa H, Inoue A, Muraoka M, Miyazaki T, Oka K, Yasukawa M. Identification of N-arachidonylglycine as the endogenous ligand for orphan G-protein-coupled receptor GPR18. Biochemical and Biophysical Research Communications. 2006 Sep;347(3):827–32. doi: 10.1016/j.bbrc.2006.06.175.; Rozec B, Gauthier C. beta3-adrenoceptors in the cardiovascular system: putative roles in human pathologies. Pharmacol Ther. 2006 Sep;111(3):652–73. doi: 10.1016/j.pharmthera.2005.12.002. PMID: 16480771.; Lee C, Rivera R, Gardell S, Dubin AE, Chun J. GPR92 as a New G12/13- and Gq-coupled Lysophosphatidic Acid Receptor That Increases cAMP, LPA5. Journal of Biological Chemistry. 2006 Aug;281(33):23589–97. doi: 10.1074/jbc.m603670200.; Wang J, Simonavicius N, Wu X, Swaminath G, Reagan J, Tian H, Ling L. Kynurenic Acid as a Ligand for Orphan G Protein-coupled Receptor GPR35. Journal of Biological Chemistry. 2006 Aug;281(31):22021–8. doi: 10.1074/jbc.m603503200.; Jacoby E, Bouhelal R, Gerspacher M, Seuwen K. The 7 TM G-protein-coupled receptor target family. ChemMedChem. 2006 Aug;1(8):761–82. doi: 10.1002/cmdc.200600134. PMID: 16902930.; Violin JD, Ren XR, Lefkowitz RJ. G-protein-coupled receptor kinase specificity for beta-arrestin recruitment to the beta2-adrenergic receptor revealed by fluorescence resonance energy transfer. J Biol Chem. 2006 Jul 21;281(29):20577–88. doi: 10.1074/jbc.m513605200. PMID: 16687412.; Comerford I, Milasta S, Morrow V, Milligan G, Nibbs R. The chemokine receptor CCX-CKR mediates effective scavenging of CCL19 in vitro. Eur J Immunol. 2006 Jul;36(7):1904–16. doi: 10.1002/eji.200535716. PMID: 16791897.; Canals M, Jenkins L, Kellett E, Milligan G. Up-regulation of the Angiotensin II Type 1 Receptor by the MAS Proto-oncogene Is Due to Constitutive Activation of Gq/G11 by MAS. Journal of Biological Chemistry. 2006 Jun;281(24):16757–67. doi: 10.1074/jbc.m601121200.; Gurevich VV, Gurevich EV. The structural basis of arrestin-mediated regulation of G-protein-coupled receptors. Pharmacology & Therapeutics. 2006 Jun;110(3):465–502. doi: 10.1016/j.pharmthera.2005.09.008.; Greenberg A, Verbalis JG. Vasopressin receptor antagonists. Kidney Int. 2006 Jun;69(12):2124–30. doi: 10.1038/sj.ki.5000432. PMID: 16672911.; Rosenkilde MM, Benned-Jensen T, Andersen H, Holst PJ, Kledal TN, Lüttichau HR, Larsen JK, Christensen JP, Schwartz TW. Molecular pharmacological phenotyping of EBI2. An orphan seven-transmembrane receptor with constitutive activity. J Biol Chem. 2006 May 12;281(19):13199–208. doi: 10.1074/jbc.m602245200. PMID: 16540462.; Huang Z, Liu S, Zhang L, Salem M, Greig GM, Chan CC, Natsumeda Y, Noguchi K. Preferential inhibition of human phosphodiesterase 4 by ibudilast. Life Sci. 2006 May 01;78(23):2663–8. doi: 10.1016/j.lfs.2005.10.026. PMID: 16313925.; Oldham WM, Hamm HE. Structural basis of function in heterotrimeric G proteins. Q Rev Biophys. 2006 May;39(2):117–66. doi: 10.1017/s0033583506004306. PMID: 16923326.; Mikels AJ, Nusse R. Purified Wnt5a Protein Activates or Inhibits ß-Catenin–TCF Signaling Depending on Receptor Context. PLoS Biol. 2006 Apr 04;4(4):e115. doi: 10.1371/journal.pbio.0040115.; Morokata T, Suzuki K, Masunaga Y, Taguchi K, Morihira K, Sato I, Fujii M, Takizawa S, Torii Y, Yamamoto N, Kaneko M, Yamada T, Takahashi K, Shimizu Y. A Novel, Selective, and Orally Available Antagonist for CC Chemokine Receptor 3. The Journal of Pharmacology and Experimental Therapeutics. 2006 Apr;317(1):244–50. doi: 10.1124/jpet.105.097048.; Infantino S, Moepps B, Thelen M. Expression and regulation of the orphan receptor RDC1 and its putative ligand in human dendritic and B cells. J Immunol. 2006 Feb 15;176(4):2197–207. doi: 10.4049/jimmunol.176.4.2197. PMID: 16455976.; Innamorati G, Piccirillo R, Bagnato P, Palmisano I, Schiaffino MV. The melanosomal/lysosomal protein OA1 has properties of a G protein-coupled receptor. Pigment Cell Research. 2006 Jan 23;19(2):125–35. doi: 10.1111/j.1600-0749.2006.00292.x.; Takai T, Takaya T, Nakano M, Akutsu H, Nakagawa A, Aimoto S, Nagai K, Ikegami T. Orexin-A is composed of a highly conserved C-terminal and a specific, hydrophilic N-terminal region, revealing the structural basis of specific recognition by the orexin-1 receptor. Journal of Peptide Science. 2006 Jan 23;12(7):443–54. doi: 10.1002/psc.747.; SEUWEN K, LUDWIG M, WOLF RM. Receptors for Protons or Lipid Messengers or Both? Journal of Receptors and Signal Transduction. 2006 Jan;26(5-6):599–610. doi: 10.1080/10799890600932220.; Slusarz MJ, Slusarz R, Ciarkowski J. Investigation of mechanism of desmopressin binding in vasopressin V2 receptor versus vasopressin V1a and oxytocin receptors: molecular dynamics simulation of the agonist-bound state in the membrane-aqueous system. Biopolymers. 2006 Apr 05;81(5):321–38. doi: 10.1002/bip.20420. PMID: 16333859.; Costes N, Merlet I, Ostrowsky K, Faillenot I, Lavenne F, Zimmer L, Ryvlin P, Le Bars D. A 18F-MPPF PET normative database of 5-HT1A receptor binding in men and women over aging. J Nucl Med. 2005 Dec;46(12):1980–9. PMID: 16330560.; Zhang JV, Ren PG, Avsian-Kretchmer O, Luo CW, Rauch R, Klein C, Hsueh AJ. Obestatin, a peptide encoded by the ghrelin gene, opposes ghrelin's effects on food intake. Science. 2005 Nov 11;310(5750):996–9. doi: 10.1126/science.1117255. PMID: 16284174.; Balabanian K, Lagane B, Infantino S, Chow KYC, Harriague J, Moepps B, Arenzana-Seisdedos F, Thelen M, Bachelerie F. The Chemokine SDF-1/CXCL12 Binds to and Signals through the Orphan Receptor RDC1 in T Lymphocytes. Journal of Biological Chemistry. 2005 Oct;280(42):35760–6. doi: 10.1074/jbc.m508234200.; Clader JW, Wang Y. Muscarinic receptor agonists and antagonists in the treatment of Alzheimer's disease. Curr Pharm Des. 2005;11(26):3353–61. doi: 10.2174/138161205774370762. PMID: 16250841.; Hasegawa M, Sugidachi A, Ogawa T, Isobe T, Jakubowski JA, Asai F. Stereoselective inhibition of human platelet aggregation by R-138727, the active metabolite of CS-747 (prasugrel, LY640315), a novel P2Y12 receptor inhibitor. Thromb Haemost. 2005 Sep;94(3):593–8. doi: 10.1160/th05-03-0208. PMID: 16268477.; Vendelin J, Pulkkinen V, Rehn M, Pirskanen A, Räisänen-Sokolowski A, Laitinen A, Laitinen LA, Kere J, Laitinen T. Characterization of GPRA, a novel G protein-coupled receptor related to asthma. Am J Respir Cell Mol Biol. 2005 Sep;33(3):262–70. doi: 10.1165/rcmb.2004-0405oc. PMID: 15947423.; Taggart AK, Kero J, Gan X, Cai TQ, Cheng K, Ippolito M, Ren N, Kaplan R, Wu K, Wu TJ, Jin L, Liaw C, Chen R, Richman J, Connolly D, Offermanns S, Wright SD, Waters MG. (D)-beta-Hydroxybutyrate inhibits adipocyte lipolysis via the nicotinic acid receptor PUMA-G. J Biol Chem. 2005 Jul 22;280(29):26649–52. doi: 10.1074/jbc.c500213200. PMID: 15929991.; Schiaffino MV, Tacchetti C. The ocular albinism type 1 (OA1) protein and the evidence for an intracellular signal transduction system involved in melanosome biogenesis. Pigment Cell Res. 2005 Aug;18(4):227–33. doi: 10.1111/j.1600-0749.2005.00240.x. PMID: 16029416.; Postma DS, Koppelman GH. Confirmation of GPRA: a putative drug target for asthma. Am J Respir Crit Care Med. 2005 Jun 15;171(12):1323–4. doi: 10.1164/rccm.2503006. PMID: 15941840.; Schiöth HB, Fredriksson R. The GRAFS classification system of G-protein coupled receptors in comparative perspective. Gen Comp Endocrinol. 2005 May 15;142(1-2):94–101. doi: 10.1016/j.ygcen.2004.12.018. PMID: 15862553.; Maurice DH. Cyclic nucleotide phosphodiesterase-mediated integration of cGMP and cAMP signaling in cells of the cardiovascular system. Front Biosci. 2005 May 01;10():1221–8. doi: 10.2741/1614. PMID: 15769620.; Ward SE, Harrington FP, Gordon LJ, Hopley SC, Scott CM, Watson JM. Discovery of the first potent, selective 5-hydroxytryptamine1D receptor antagonist. J Med Chem. 2005 May 19;48(10):3478–80. doi: 10.1021/jm049039v. PMID: 15887956.; Hooper JE, Scott MP. Communicating with Hedgehogs. Nature Reviews Molecular Cell Biology. 2005 Apr;6(4):306–17. doi: 10.1038/nrm1622.; Jeon YH, Heo Y-, Kim CM, Hyun Y-, Lee TG, Ro S, Cho JM. Phosphodiesterase: overview of protein structures, potential therapeutic applications and recent progress in drug development. Cellular and Molecular Life Sciences. 2005 Mar 29;62(11):1198–220. doi: 10.1007/s00018-005-4533-5.; Revankar CM, Cimino DF, Sklar LA, Arterburn JB, Prossnitz ER. A transmembrane intracellular estrogen receptor mediates rapid cell signaling. Science. 2005 Mar 11;307(5715):1625–30. doi: 10.1126/science.1106943. PMID: 15705806.; Arita M, Bianchini F, Aliberti J, Sher A, Chiang N, Hong S, Yang R, Petasis NA, Serhan CN. Stereochemical assignment, antiinflammatory properties, and receptor for the omega-3 lipid mediator resolvin E1. J Exp Med. 2005 Mar 07;201(5):713–22. PMID: 15753205; PMCID: PMC2212834.; Lindemann L, Ebeling M, Kratochwil NA, Bunzow JR, Grandy DK, Hoener MC. Trace amine-associated receptors form structurally and functionally distinct subfamilies of novel G protein-coupled receptors. Genomics. 2005 Mar;85(3):372–85. doi: 10.1016/j.ygeno.2004.11.010. PMID: 15718104.; Wellendorph P, Hansen KB, Balsgaard A, Greenwood JR, Egebjerg J, Bräuner-Osborne H. Deorphanization of GPRC6A: a promiscuous L-alpha-amino acid receptor with preference for basic amino acids. Mol Pharmacol. 2005 Mar;67(3):589–97. doi: 10.1124/mol.104.007559. PMID: 15576628.; Turner MR, Rabiner EA, Hammers A, Al-Chalabi A, Grasby PM, Shaw CE, Brooks DJ, Leigh PN. [11C]-WAY100635 PET demonstrates marked 5-HT1A receptor changes in sporadic ALS. Brain. 2005 Apr;128(Pt 4):896–905. doi: 10.1093/brain/awh428. PMID: 15689356.; Thomas P, Pang Y, Filardo EJ, Dong J. Identity of an estrogen membrane receptor coupled to a G protein in human breast cancer cells. Endocrinology. 2005 Feb;146(2):624–32. doi: 10.1210/en.2004-1064. PMID: 15539556.; Koehler JA, Yusta B, Drucker DJ. The HeLa cell glucagon-like peptide-2 receptor is coupled to regulation of apoptosis and ERK1/2 activation through divergent signaling pathways. Mol Endocrinol. 2005 Feb;19(2):459–73. doi: 10.1210/me.2004-0196. PMID: 15471943.; Baker JG. The selectivity of ß-adrenoceptor antagonists at the human ß1, ß2 and ß3 adrenoceptors. British J Pharmacology. 2005 Feb;144(3):317–22. doi: 10.1038/sj.bjp.0706048.; Qiu X, Kumbalasiri T, Carlson SM, Wong KY, Krishna V, Provencio I, Berson DM. Induction of photosensitivity by heterologous expression of melanopsin. Nature. 2005 Feb 17;433(7027):745–9. doi: 10.1038/nature03345. PMID: 15674243.; Liu C, Kuei C, Sutton S, Chen J, Bonaventure P, Wu J, Nepomuceno D, Kamme F, Tran D, Zhu J, Wilkinson T, Bathgate R, Eriste E, Sillard R, Lovenberg TW. INSL5 Is a High Affinity Specific Agonist for GPCR142 (GPR100). Journal of Biological Chemistry. 2005 Jan;280(1):292–300. doi: 10.1074/jbc.m409916200.; Chen CK. The vertebrate phototransduction cascade: amplification and termination mechanisms. Rev Physiol Biochem Pharmacol. 2005;154():101–21. doi: 10.1007/s10254-005-0004-0. PMID: 16634148.; Siderovski DP, Willard FS. The GAPs, GEFs, and GDIs of heterotrimeric G-protein alpha subunits. Int J Biol Sci. 2005;1(2):51–66. PMID: 15951850; PMCID: PMC1142213.; Migeotte I, Riboldi E, Franssen JD, Grégoire F, Loison C, Wittamer V, Detheux M, Robberecht P, Costagliola S, Vassart G, Sozzani S, Parmentier M, Communi D. Identification and characterization of an endogenous chemotactic ligand specific for FPRL2. J Exp Med. 2005 Jan 03;201(1):83–93. PMID: 15623572; PMCID: PMC2212760.; Hirasawa A, Tsumaya K, Awaji T, Katsuma S, Adachi T, Yamada M, Sugimoto Y, Miyazaki S, Tsujimoto G. Free fatty acids regulate gut incretin glucagon-like peptide-1 secretion through GPR120. Nat Med. 2005 Jan;11(1):90–4. doi: 10.1038/nm1168. PMID: 15619630.; Holst B, Holliday ND, Bach A, Elling CE, Cox HM, Schwartz TW. Common Structural Basis for Constitutive Activity of the Ghrelin Receptor Family. Journal of Biological Chemistry. 2004 Dec;279(51):53806–17. doi: 10.1074/jbc.m407676200.; Beeh KM, Beier J, Lerch C, Schulz AK, Buhl R. Effects of piclamilast, a selective phosphodiesterase-4 inhibitor, on oxidative burst of sputum cells from mild asthmatics and stable COPD patients. Lung. 2004;182(6):369–77. doi: 10.1007/s00408-004-2518-z. PMID: 15765929.; Wang J, Kon J, Mogi C, Tobo M, Damirin A, Sato K, Komachi M, Malchinkhuu E, Murata N, Kimura T, Kuwabara A, Wakamatsu K, Koizumi H, Uede T, Tsujimoto G, Kurose H, Sato T, Harada A, Misawa N, Tomura H, Okajima F. TDAG8 Is a Proton-sensing and Psychosine-sensitive G-protein-coupled Receptor. Journal of Biological Chemistry. 2004 Oct;279(44):45626–33. doi: 10.1074/jbc.m406966200.; Kwakkenbos MJ, Pouwels W, Matmati M, Stacey M, Lin HH, Gordon S, van Lier RA, Hamann J. Expression of the largest CD97 and EMR2 isoforms on leukocytes facilitates a specific interaction with chondroitin sulfate on B cells. J Leukoc Biol. 2005 Jan;77(1):112–9. doi: 10.1189/jlb.0704402. PMID: 15498814.; Murakami N, Yokomizo T, Okuno T, Shimizu T. G2A Is a Proton-sensing G-protein-coupled Receptor Antagonized by Lysophosphatidylcholine. Journal of Biological Chemistry. 2004 Oct;279(41):42484–91. doi: 10.1074/jbc.m406561200.; Wilson RJ, Rhodes SA, Wood RL, Shield VJ, Noel LS, Gray DW, Giles H. Functional pharmacology of human prostanoid EP2 and EP4 receptors. Eur J Pharmacol. 2004 Oct 06;501(1-3):49–58. doi: 10.1016/j.ejphar.2004.08.025. PMID: 15464062.; Choi S, Haggart D, Toll L, Cuny GD. Synthesis, receptor binding and functional studies of mesoridazine stereoisomers. Bioorganic & Medicinal Chemistry Letters. 2004 Sep;14(17):4379–82. doi: 10.1016/j.bmcl.2004.06.078.; Belibi FA, Reif G, Wallace DP, Yamaguchi T, Olsen L, Li H, Helmkamp GM, Grantham JJ. Cyclic AMP promotes growth and secretion in human polycystic kidney epithelial cells. Kidney Int. 2004 Sep;66(3):964–73. doi: 10.1111/j.1523-1755.2004.00843.x. PMID: 15327388.; Shehabi Y, Ruettimann U, Adamson H, Innes R, Ickeringill M. Dexmedetomidine infusion for more than 24 hours in critically ill patients: sedative and cardiovascular effects. Intensive Care Med. 2004 Dec;30(12):2188–96. doi: 10.1007/s00134-004-2417-z. PMID: 15338124.; Xu YL, Reinscheid RK, Huitron-Resendiz S, Clark SD, Wang Z, Lin SH, Brucher FA, Zeng J, Ly NK, Henriksen SJ, de Lecea L, Civelli O. Neuropeptide S: a neuropeptide promoting arousal and anxiolytic-like effects. Neuron. 2004 Aug 19;43(4):487–97. doi: 10.1016/j.neuron.2004.08.005. PMID: 15312648.; Heinrich T, Böttcher H, Gericke R, Bartoszyk GD, Anzali S, Seyfried CA, Greiner HE, Van Amsterdam C. Synthesis and structure--activity relationship in a class of indolebutylpiperazines as dual 5-HT(1A) receptor agonists and serotonin reuptake inhibitors. J Med Chem. 2004 Sep 09;47(19):4684–92. doi: 10.1021/jm040793q. PMID: 15341484.; Kanda N, Watanabe S. 17ß-Estradiol Stimulates the Growth of Human Keratinocytes by Inducing Cyclin D2 Expression. Journal of Investigative Dermatology. 2004 Aug;123(2):319–28. doi: 10.1111/j.0022-202x.2004.12645.x.; Cao X, Cismowski MJ, Sato M, Blumer JB, Lanier SM. Identification and characterization of AGS4: a protein containing three G-protein regulatory motifs that regulate the activation state of Gialpha. J Biol Chem. 2004 Jun 25;279(26):27567–74. doi: 10.1074/jbc.m312786200. PMID: 15096500.; Wellendorph P, Bräuner-Osborne H. Molecular cloning, expression, and sequence analysis of GPRC6A, a novel family C G-protein-coupled receptor. Gene. 2004 Jun 23;335():37–46. doi: 10.1016/j.gene.2004.03.003. PMID: 15194188.; Ying G, Iribarren P, Zhou Y, Gong W, Zhang N, Yu ZX, Le Y, Cui Y, Wang JM. Humanin, a newly identified neuroprotective factor, uses the G protein-coupled formylpeptide receptor-like-1 as a functional receptor. J Immunol. 2004 Jun 01;172(11):7078–85. doi: 10.4049/jimmunol.172.11.7078. PMID: 15153530.; He W, Miao FJ, Lin DC, Schwandner RT, Wang Z, Gao J, Chen JL, Tian H, Ling L. Citric acid cycle intermediates as ligands for orphan G-protein-coupled receptors. Nature. 2004 May 13;429(6988):188–93. doi: 10.1038/nature02488. PMID: 15141213.; Hsieh JC. Specificity of WNT-receptor interactions. Front Biosci. 2004 May 01;9():1333–8. doi: 10.2741/1321. PMID: 14977548.; Bolli MH, Marfurt J, Grisostomi C, Boss C, Binkert C, Hess P, Treiber A, Thorin E, Morrison K, Buchmann S, Bur D, Ramuz H, Clozel M, Fischli W, Weller T. Novel benzo[1,4]diazepin-2-one derivatives as endothelin receptor antagonists. J Med Chem. 2004 May 20;47(11):2776–95. doi: 10.1021/jm031115r. PMID: 15139756.; Bonecchi R, Locati M, Galliera E, Vulcano M, Sironi M, Fra AM, Gobbi M, Vecchi A, Sozzani S, Haribabu B, Van Damme J, Mantovani A. Differential recognition and scavenging of native and truncated macrophage-derived chemokine (macrophage-derived chemokine/CC chemokine ligand 22) by the D6 decoy receptor. J Immunol. 2004 Apr 15;172(8):4972–6. doi: 10.4049/jimmunol.172.8.4972. PMID: 15067078.; De La Luz Sierra M, Yang F, Narazaki M, Salvucci O, Davis D, Yarchoan R, Zhang HH, Fales H, Tosato G. Differential processing of stromal-derived factor-1alpha and stromal-derived factor-1beta explains functional diversity. Blood. 2004 Apr 01;103(7):2452–9. doi: 10.1182/blood-2003-08-2857. PMID: 14525775.; Kalipatnapu S, Pucadyil TJ, Harikumar KG, Chattopadhyay A. Ligand binding characteristics of the human serotonin1A receptor heterologously expressed in CHO cells. Biosci Rep. 2004 Apr;24(2):101–15. doi: 10.1007/s10540-004-7191-1. PMID: 15628665.; Ogden SK, Ascano M, Stegman MA, Robbins DJ. Regulation of Hedgehog signaling: a complex story. Biochemical Pharmacology. 2004 Mar;67(5):805–14. doi: 10.1016/j.bcp.2004.01.002.; Roh J, Chang CL, Bhalla A, Klein C, Hsu SYT. Intermedin Is a Calcitonin/Calcitonin Gene-related Peptide Family Peptide Acting through the Calcitonin Receptor-like Receptor/Receptor Activity-modifying Protein Receptor Complexes. Journal of Biological Chemistry. 2004 Feb;279(8):7264–74. doi: 10.1074/jbc.m305332200.; Gupte J, Cutler G, Chen JL, Tian H. Elucidation of signaling properties of vasopressin receptor-related receptor 1 by using the chimeric receptor approach. Proc Natl Acad Sci U S A. 2004 Feb 10;101(6):1508–13. PMID: 14757815; PMCID: PMC341764.; Deo DD, Bazan NG, Hunt JD. Activation of platelet-activating factor receptor-coupled G alpha q leads to stimulation of Src and focal adhesion kinase via two separate pathways in human umbilical vein endothelial cells. J Biol Chem. 2004 Jan 30;279(5):3497–508. doi: 10.1074/jbc.m304497200. PMID: 14617636.; Kwakkenbos MJ, Kop EN, Stacey M, Matmati M, Gordon S, Lin HH, Hamann J. The EGF-TM7 family: a postgenomic view. Immunogenetics. 2004 Jan;55(10):655–66. doi: 10.1007/s00251-003-0625-2. PMID: 14647991.; Elagoz A, Henderson D, Babu PS, Salter S, Grahames C, Bowers L, Roy M, Laplante P, Grazzini E, Ahmad S, Lembo PMC. A truncated form of CKß8-1 is a potent agonist for human formyl peptide-receptor-like 1 receptor. British J Pharmacology. 2004 Jan;141(1):37–46. doi: 10.1038/sj.bjp.0705592.; Kuwasako K, Cao YN, Nagoshi Y, Tsuruda T, Kitamura K, Eto T. Characterization of the human calcitonin gene-related peptide receptor subtypes associated with receptor activity-modifying proteins. Mol Pharmacol. 2004 Jan;65(1):207–13. doi: 10.1124/mol.65.1.207. PMID: 14722252.; Zanchetti A. Clinical pharmacodynamics of nebivolol: new evidence of nitric oxide-mediated vasodilating activity and peculiar haemodynamic properties in hypertensive patients. Blood Press Suppl. 2004 Oct;1():17–32. doi: 10.1080/08038020410016548. PMID: 15587108.; Stroe AF, Gheorghiade M. Carvedilol: beta-blockade and beyond. Rev Cardiovasc Med. 2004;5 Suppl 1():S18–27. PMID: 15184840.; Debruyne FM. Gonadotropin-releasing hormone antagonist in the management of prostate cancer. Rev Urol. 2004;6 Suppl 7():S25–32. PMID: 16985933; PMCID: PMC1472892.; Liu C, Chen J, Sutton S, Roland B, Kuei C, Farmer N, Sillard R, Lovenberg TW. Identification of Relaxin-3/INSL7 as a Ligand for GPCR142. Journal of Biological Chemistry. 2003 Dec;278(50):50765–70. doi: 10.1074/jbc.m308996200.; Liu C, Eriste E, Sutton S, Chen J, Roland B, Kuei C, Farmer N, Jörnvall H, Sillard R, Lovenberg TW. Identification of Relaxin-3/INSL7 as an Endogenous Ligand for the Orphan G-protein-coupled Receptor GPCR135. Journal of Biological Chemistry. 2003 Dec;278(50):50754–64. doi: 10.1074/jbc.m308995200.; Cabrera-Vera TM, Vanhauwe J, Thomas TO, Medkova M, Preininger A, Mazzoni MR, Hamm HE. Insights into G protein structure, function, and regulation. Endocr Rev. 2003 Dec;24(6):765–81. doi: 10.1210/er.2000-0026. PMID: 14671004.; Kanda N, Watanabe S. 17ß-Estradiol Inhibits Oxidative Stress-Induced Apoptosis in Keratinocytes by Promoting Bcl-2 Expression. Journal of Investigative Dermatology. 2003 Dec;121(6):1500–9. doi: 10.1111/j.1523-1747.2003.12617.x.; Ruilope LM, Segura J. Losartan and other angiotensin II antagonists for nephropathy in type 2 diabetes mellitus: a review of the clinical trial evidence. Clin Ther. 2003 Dec;25(12):3044–64. doi: 10.1016/s0149-2918(03)90091-9. PMID: 14749145.; Caicedo A, Pereira E, Margolskee RF, Roper SD. Role of the G-Protein Subunit a-Gustducin in Taste Cell Responses to Bitter Stimuli. J. Neurosci. 2003 Oct 29;23(30):9947–52. doi: 10.1523/jneurosci.23-30-09947.2003.; Tarttelin EE, Bellingham J, Hankins MW, Foster RG, Lucas RJ. Neuropsin (Opn5): a novel opsin identified in mammalian neural tissue. FEBS Lett. 2003 Nov 20;554(3):410–6. doi: 10.1016/s0014-5793(03)01212-2. PMID: 14623103.; Sugo T, Murakami Y, Shimomura Y, Harada M, Abe M, Ishibashi Y, Kitada C, Miyajima N, Suzuki N, Mori M, Fujino M. Identification of urotensin II-related peptide as the urotensin II-immunoreactive molecule in the rat brain. Biochemical and Biophysical Research Communications. 2003 Oct;310(3):860–8. doi: 10.1016/j.bbrc.2003.09.102.; Seminara SB, Messager S, Chatzidaki EE, Thresher RR, Acierno JS, Shagoury JK, Bo-Abbas Y, Kuohung W, Schwinof KM, Hendrick AG, Zahn D, Dixon J, Kaiser UB, Slaugenhaupt SA, Gusella JF, O'Rahilly S, Carlton MB, Crowley WF, Aparicio SA, Colledge WH. The GPR54 gene as a regulator of puberty. N Engl J Med. 2003 Oct 23;349(17):1614–27. doi: 10.1056/nejmoa035322. PMID: 14573733.; Stacey M, Chang GW, Davies JQ, Kwakkenbos MJ, Sanderson RD, Hamann J, Gordon S, Lin HH. The epidermal growth factor-like domains of the human EMR2 receptor mediate cell attachment through chondroitin sulfate glycosaminoglycans. Blood. 2003 Oct 15;102(8):2916–24. doi: 10.1182/blood-2002-11-3540. PMID: 12829604.; Wittamer V, Franssen JD, Vulcano M, Mirjolet JF, Le Poul E, Migeotte I, Brézillon S, Tyldesley R, Blanpain C, Detheux M, Mantovani A, Sozzani S, Vassart G, Parmentier M, Communi D. Specific recruitment of antigen-presenting cells by chemerin, a novel processed ligand from human inflammatory fluids. J Exp Med. 2003 Oct 06;198(7):977–85. PMID: 14530373; PMCID: PMC2194212.; Wakasugi K, Nakano T, Morishima I. Oxidized human neuroglobin acts as a heterotrimeric Galpha protein guanine nucleotide dissociation inhibitor. J Biol Chem. 2003 Sep 19;278(38):36505–12. doi: 10.1074/jbc.m305519200. PMID: 12860983.; Ludwig MG, Vanek M, Guerini D, Gasser JA, Jones CE, Junker U, Hofstetter H, Wolf RM, Seuwen K. Proton-sensing G-protein-coupled receptors. Nature. 2003 Sep 04;425(6953):93–8. doi: 10.1038/nature01905. PMID: 12955148.; Tournamille C, Filipe A, Wasniowska K, Gane P, Lisowska E, Cartron JP, Colin Y, Le Van Kim C. Structure-function analysis of the extracellular domains of the Duffy antigen/receptor for chemokines: characterization of antibody and chemokine binding sites. Br J Haematol. 2003 Sep;122(6):1014–23. doi: 10.1046/j.1365-2141.2003.04533.x. PMID: 12956774.; Jiang Y, Luo L, Gustafson EL, Yadav D, Laverty M, Murgolo N, Vassileva G, Zeng M, Laz TM, Behan J, Qiu P, Wang L, Wang S, Bayne M, Greene J, Monsma F, Zhang FL. Identification and Characterization of a Novel RF-amide Peptide Ligand for Orphan G-protein-coupled Receptor SP9155. Journal of Biological Chemistry. 2003 Jul;278(30):27652–7. doi: 10.1074/jbc.m302945200.; Xanthou G, Duchesnes CE, Williams TJ, Pease JE. CCR3 functional responses are regulated by both CXCR3 and its ligands CXCL9, CXCL10 and CXCL11. Eur J Immunol. 2003 Aug;33(8):2241–50. doi: 10.1002/eji.200323787. PMID: 12884299.; Zhang JY, Nawoschik S, Kowal D, Smith D, Spangler T, Ochalski R, Schechter L, Dunlop J. Characterization of the 5-HT6 receptor coupled to Ca2+ signaling using an enabling chimeric G-protein. Eur J Pharmacol. 2003 Jul 04;472(1-2):33–8. doi: 10.1016/s0014-2999(03)01855-7. PMID: 12860470.; Santos RA, Simoes e Silva AC, Maric C, Silva DM, Machado RP, de Buhr I, Heringer-Walther S, Pinheiro SV, Lopes MT, Bader M, Mendes EP, Lemos VS, Campagnole-Santos MJ, Schultheiss HP, Speth R, Walther T. Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor Mas. Proc Natl Acad Sci U S A. 2003 Jul 08;100(14):8258–63. PMID: 12829792; PMCID: PMC166216.; Nuttall SL, Routledge HC, Kendall MJ. A comparison of the beta1-selectivity of three beta1-selective beta-blockers. J Clin Pharm Ther. 2003 Jun;28(3):179–86. doi: 10.1046/j.1365-2710.2003.00477.x. PMID: 12795776.; Cao L, Weil MH, Sun S, Tang W. Vasopressor agents for cardiopulmonary resuscitation. J Cardiovasc Pharmacol Ther. 2003 Jun;8(2):115–21. doi: 10.1177/107424840300800204. PMID: 12808484.; Bräuer AU, Savaskan NE, Kühn H, Prehn S, Ninnemann O, Nitsch R. A new phospholipid phosphatase, PRG-1, is involved in axon growth and regenerative sprouting. Nat Neurosci. 2003 Jun;6(6):572–8. doi: 10.1038/nn1052. PMID: 12730698.; Herbert JM, Savi P. P2Y12, a new platelet ADP receptor, target of clopidogrel. Semin Vasc Med. 2003 May;3(2):113–22. doi: 10.1055/s-2003-40669. PMID: 15199474.; Tanaka H, Yoshida T, Miyamoto N, Motoike T, Kurosu H, Shibata K, Yamanaka A, Williams SC, Richardson JA, Tsujino N, Garry MG, Lerner MR, King DS, O'Dowd BF, Sakurai T, Yanagisawa M. Characterization of a family of endogenous neuropeptide ligands for the G protein-coupled receptors GPR7 and GPR8. Proc. Natl. Acad. Sci. U.S.A. 2003 Apr 28;100(10):6251–6. doi: 10.1073/pnas.0837789100.; Mzhavia N, Pan H, Che FY, Fricker LD, Devi LA. Characterization of endothelin-converting enzyme-2. Implication for a role in the nonclassical processing of regulatory peptides. J Biol Chem. 2003 Apr 25;278(17):14704–11. PMID: 12560336; PMCID: PMC3862352.; Neuschäfer-Rube F, Engemaier E, Koch S, Böer U, Püschel GP. Identification by site-directed mutagenesis of amino acids contributing to ligand-binding specificity or signal transduction properties of the human FP prostanoid receptor. Biochem J. 2003 Apr 15;371(Pt 2):443–9. PMID: 12519077; PMCID: PMC1223288.; Kalant D, Cain SA, Maslowska M, Sniderman AD, Cianflone K, Monk PN. The Chemoattractant Receptor-like Protein C5L2 Binds the C3a des-Arg77/Acylation-stimulating Protein. Journal of Biological Chemistry. 2003 Mar;278(13):11123–9. doi: 10.1074/jbc.m206169200.; Lüttichau HR, Clark-Lewis I, Jensen PØ, Moser C, Gerstoft J, Schwartz TW. A Highly Selective CCR2 Chemokine Agonist Encoded by Human Herpesvirus 6. Journal of Biological Chemistry. 2003 Mar;278(13):10928–33. doi: 10.1074/jbc.m211329200.; Brown AJ, Goldsworthy SM, Barnes AA, Eilert MM, Tcheang L, Daniels D, Muir AI, Wigglesworth MJ, Kinghorn I, Fraser NJ, Pike NB, Strum JC, Steplewski KM, Murdock PR, Holder JC, Marshall FH, Szekeres PG, Wilson S, Ignar DM, Foord SM, Wise A, Dowell SJ. The Orphan G Protein-coupled Receptors GPR41 and GPR43 Are Activated by Propionate and Other Short Chain Carboxylic Acids. Journal of Biological Chemistry. 2003 Mar;278(13):11312–9. doi: 10.1074/jbc.m211609200.; Briscoe CP, Tadayyon M, Andrews JL, Benson WG, Chambers JK, Eilert MM, Ellis C, Elshourbagy NA, Goetz AS, Minnick DT, Murdock PR, Sauls HR, Shabon U, Spinage LD, Strum JC, Szekeres PG, Tan KB, Way JM, Ignar DM, Wilson S, Muir AI